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ABSTRACT 
Porcine reproductive and respiratory syndrome virus continues to be a significant 
problem for pork producers.  The aim of this body of work was to help stakeholders 
control and prevention infection with this virus.  A literature review of currently 
available diagnostic tests and guidelines for their interpretation serves as a resource for 
producers, practitioners, and researchers.  The research focus was to evaluate two novel 
methods to develop improved modified live vaccines.  The efficacy of viral chimeras 
constructed from a commercially available vaccine and a virulent wild-type isolate and 
the ability to attenuate wild-type isolates with a unique cell passage process are reported.  
Both techniques proved to be capable of developing potential vaccine candidates. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
 Porcine reproductive and respiratory syndrome virus (PRRSV) was first 
recognized in the early 1990s as a cause of severe reproductive losses, respiratory 
disease, increased mortality, and reduced growth rates in pigs [1-3].  Current control and 
prevention strategies rely heavily on the use of diagnostics to develop herd health 
management strategies to optimize production.  A thorough understanding of the 
diagnostic approach, available tests, and test result interpretation are vital components to 
developing the best strategies for disease control.  However, diagnostic tests are rapidly 
changing and it is a challenge for veterinarians and other stakeholders to remain current 
with available techniques and technologies.  Another challenge to successful control and 
prevention programs revolves around the imperfect tools currently available to increase 
and stabilize herd immunity against PRRS.  Current commercial vaccines are widely 
used and help limit losses but have room for improvement.  This research focuses on the 
search for improved vaccines. 
PRRSV is an enveloped, single stranded RNA virus classified within the family 
Arteriviridae under the order Nidovirales.  Species of PRRSV form two major genetic 
lineages and are classified into two genotypes, type 1 (European) or type 2 (North 
American).  There is a large amount of genetic diversity within PRRS isolates, which 
creates problems for diagnostic testing and developing cross protective vaccines.  The 
prototype genomes for type 1 (Lelystad virus) and type 2 (VR-2332) genotypes vary by 
approximately 44% in nucleotide sequence composition.  Known sequence variation 
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within a genotype varies by up to 30% in type 1 and 21% in type 2 viruses [4].  The 
PRRSV genome is approximately 15,000 kilobases and is organized into at least 10 open 
reading frames, numbered (1a, 1b, 2, 2b, 5a, and 3-7,) [4, 5].  Transmission of the virus 
occurs via intranasal, intramuscular, oral, intrauterine, and vaginal exposure.  Pigs can 
develop infection via parenteral exposure, direct contact with infected pigs, contact with 
contaminated fomites, exposure to insect vectors, and exposure via infectious aerosols 
[6-8]. 
 Clinically, PRRS causes problems in swine breeding herds and in growing pigs 
which can vary from asymptomatic to devastating disease.  The large variety of clinical 
signs are influenced by isolate virulence, susceptibility of host animals, host immune 
status, concurrent infections, and other management factors.  Disease in the breeding 
herd is characterized initially by anorexia, pyrexia, and hyperpnea which are followed by 
reproductive failure (abortions, irregular returns to estrus, and reduced live born piglets) 
and high preweaning mortality in suckling piglets.  In growing pig herds infection is 
characterized by anorexia, lethargy, cutaneous hyperemia, hyperpnea, rough hair coats, 
reduced weight gains, and increased severity of endemic infections.   
 To prevent disease associated with PRRS, producers focus on preventing the 
entrance of new viral isolates into herds through strict biosecurity measures for all 
materials, people, and pigs entering the farm.  Other prevention strategies focus on 
increasing the host adaptive immune system for potential future infections.  Immune 
enhancement can be accomplished through contact with other infected animals, 
intentional exposure with infectious virus, or vaccination.  Contact with infected animals 
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becomes difficult to routinely accomplish as the herd becomes immune to the virus over 
time and may stop shedding virus.  Intentional exposure to infectious virus has 
significant inherent risks and requires high quality standard controls.  Use of vaccine is a 
much safer and more consistent approach to increase herd immunity. 
 There are a variety of PRRSV vaccines available around the world which 
includes modified live vaccine (MLV) products, killed products, and subunit vaccines.  
In general, there is scant evidence that immunization with non-replicating or subunit 
products by themselves provide protection against homologous or heterologous 
infection.  However, numerous studies have shown that live attenuated isolates are 
capable of reducing clinical signs and lesions by homologous and heterologous virus [9].  
Further, in-depth reviews of killed vs. MLV products, strategies, and results have been 
completed elsewhere and thus are not reviewed in this thesis [9-14].   
 Currently available MLV products were attenuated by continuous passage of an 
isolate in cell culture until random genetic changes decreased the virulence of the virus 
in pigs.  This process is a proven technique to develop effective vaccines, but is 
laborious, time consuming, and relatively low yielding.  The final products replicate to 
some degree in pigs, and provide an unpredictable level of efficacy against subsequent 
heterologous challenges.  The safety of vaccines prone to mutation and capable of 
replicating in the pig host has raised some concern over the possibility of reverting to 
virulence in the field.  Furthermore, attenuated vaccines are generally indistinguishable 
from pathogenic wild type isolates with most diagnostic testing options making it 
difficult to differentiate vaccinated from infected animals.  Clearly, the swine industry 
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would benefit from the development of vaccines capable of being produced quickly, 
with increased safety, and with characteristics allowing for the differentiation of pigs 
vaccinated from those infected.  The original research reported in this thesis focuses on 
the development of these technologies. 
 Thesis Organization 
Chapter 2 serves as a literature review of PRRSV diagnostics.  A comprehensive 
review of PRRS diagnostics has not been completed since 2002 [15].  Since then, the 
growing quantity of available research continues to add to our expanding knowledge of 
the virus.  The PubMed® database identified 1,216 articles published in peer-reviewed 
journals since 2002 pertinent to PRRSV [figure 1][16].  Of those, many report 
significant advances in technologies and techniques to collect/transport/detect viral 
antigens, viral RNA, and anti-PRRSv antibodies in a growing amount of samples.  A 
review of diagnostics is pertinent to the evaluation of vaccine efficacy, development of 
future vaccines, and is extremely important for development of management strategies to 
control and/or eliminate PRRSV from a herd.  This manuscript is to be submitted for 
publication to Animal Health Research Reviews.   
The following chapters cover original work which focused on strategies to 
develop improved PRRSV MLVs.  Chapter 3 contains original research on the 
development and efficacy of PRRSV chimeras within a growing pig controlled challenge 
model.  This manuscript was published in Vaccine 28 (2010) 2679-2686.  The first 
author’s role in the research was to develop, execute, interpret, and document the animal 
testing phases of the study.  The infectious chimeras were provided by Dr. Kay 
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Faaberg’s laboratory for testing.  Chapter 4 contains original research on the generation 
of attenuated isolates and their screening for virulence within pregnant gilt and growing 
pig challenge models.  The first author’s role in this work included the development, 
execution, interpretation, and documentation of the animal testing phases of the study.  
The passaged isolates were created and provided by the Boehringer Ingelheim 
Vetmedica Incorporated Research and Development team.   
For both trials, the daily animal care was executed by an unbiased third party 
while the first author was involved with the animal vaccinations, euthanasia, and 
necropsies.  Diagnostics were performed by the first author with the exception of 
ELISAs and sequencing which were performed by external third parties.   
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Figure 1.  PubMed identified Porcine Reproductive and Respiratory Syndrome 
Virus manuscripts published per year. 
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CHAPTER 2: PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME 
VIRUS: A REVIEW OF TEST MECHANISMS, DIAGNOSTIC STRATEGIES 
AND INTERPRETATION 
 
A paper to be submitted to Animal Health Research Reviews 
Joshua Scott Ellingson 
Abstract 
 Porcine Reproductive and Respiratory Syndrome is one of the most economically 
devastating pathogens affecting the swine industry.  Prevention, control, and elimination 
strategies rely on the proper application of diagnostics to describe the current infection 
and exposure status of individual pigs and herds.  The correct use of diagnostics includes 
determining the diagnostic objective, identifying the animal subpopulation to sample, 
choosing appropriate tests to use, calculating the number of samples necessary, and 
classifying the herd in a meaningful way based on all available data.  Diagnostic 
technologies and strategies are evolving with each new research discovery which 
challenges veterinarians, researchers, producers, and other stakeholders to remain 
current with best practices.  Diagnostic approaches, available tests, and guidelines for 
interpretation are reviewed herein. 
1. Introduction 
Porcine Reproductive and Respiratory Syndrome (PRRS) is one of the most 
economically significant pathogens affecting the swine industry worldwide.  PRRS has 
been reducing producer profits since the late 1980’s and has since become endemic in 
most pork producing regions.  A recent economic analysis estimated the total cost to the 
United States swine industry at $664 million annually or $1.8 million per day [1].  
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Current prevention and control strategies include intensive biosecurity practices, 
vaccination and rigorous diagnostic surveillance strategies at the individual farm level.  
Recognizing the difficulty in preventing the transmission of porcine reproductive and 
respiratory syndrome virus (PRRSV) from positive farms to adjacent negative farms, 
larger scale “area regional control and elimination” (ARC&E) projects have been 
initiated.  These programs have been developed to coordinate the communication of 
PRRS status, control strategies, and elimination plans for large geographic regions 
including as many as 500 individual farms.  To date, the success of PRRS control and 
elimination programs at the individual farm and regional level has had variable results. 
Effective PRRS control, elimination, and prevention plans require significant 
capital investment of producers, steadfast commitment from the farm staff, and effective 
diagnostic tests to correctly classify the status of animals.  Equally important as having 
rapid, sensitive, and specific diagnostic tests available is the requirement for correct test 
result interpretation.  Interpretation is the final piece to the diagnostic process which 
helps safeguard producers from economic losses associated with infection.   
Significant time and financial resources have been invested to continually 
improve and refine diagnostic approaches and assays.  Available PRRSV diagnostics 
evolve regularly, making it challenging for veterinarians and industry stakeholders to 
remain current.  This paper reviews diagnostic approaches, available assays, and 
guidelines for interpretation. 
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2. Diagnostic Approach 
2.1 Determine objective 
Diagnostics are performed to satisfy a defined objective.  Objectives may include: 
detection of infection, determination of prevalence within a population, confirmation of 
exposure/vaccination, or to determine the timing of infection [2].  All diagnostic 
approaches can have an effect on management decisions for individual animals or the 
entire herd or funds are being wasted.  For example, if a boar tests positive for PRRSV 
via PCR semen would not be sold, but semen would be sold and distributed if the test 
result was negative.  Discretion must be used to ensure the prudent use of producer funds 
for diagnostic workups.  Diagnostic approaches should be synthesized to answer a 
particular objective with an acceptable level of confidence in the most efficient manner. 
2.2 Determine Population 
Once the objective has been defined, the next step is to determine the population 
to sample.  Testing can either be directed at an individual animal or an entire population.  
When testing individuals, assays with the highest sensitivity are sought to attain the 
highest level of confidence.  Timing plays a critical role in testing individuals as viremia, 
viral shedding, antibody responses, and histological lesions have finite durations.  
Likewise, interpreting individual test results may not reflect the status of the entire herd 
as the timeline of infection will vary for each individual animal.  With herd level testing, 
animal selection is very important.  Objectives should determine the animal population 
to target which can include: young, old, recently comingled, or diseased animals.  
12 
 
Individual test results provide specific animal status while herd level diagnostics provide 
an inference of the population.   
2.3 Determine test and interpret individual test results in light of clinical signs 
 Once the objective and targeted population has been determined, the appropriate 
test should be selected.  PRRSV diagnostic tests can be broken up into two main 
categories: 1) viral detection or 2) viral exposure.  Viral detection requires collection of 
virus laden tissue, bronchoalveolar lavage (BAL) fluid, thoracic fluid, semen, blood, oral 
fluid, or environmental samples and relies heavily on molecular techniques, but can also 
be accomplished with virus isolation and less specific techniques such as electron 
microscopy or tissue immunohistochemistry.  Detection of viral exposure is based on 
antibody production and requires blood, oral fluid collection, or muscle transudate.   
Detection of Virus 
RT-PCR 
 Molecular technologies have been an area of rapid development and extensive 
use by pig producers for detection of PRRSV.  Numerous (polymerase chain reaction) 
PCR assays have been described since the first assays were developed in the mid-1990s 
[3, 4].  The reverse transcriptase (RT-PCR) is used to detect PRRS ribonucleic acid 
(RNA) in clinical specimens, now including: serum, oral fluid, lung, tonsil, lymph node, 
BAL fluid, heart, kidney, spleen, thymus, semen, and thoracic fluid.  Compared with 
other available tests, RT-PCR is also the test of choice for fetuses when vertical 
transmission is suspected [5].  Viral RNA is first extracted from the specimen, converted 
to DNA through a reverse transcriptase step, and then the complementary viral DNA is 
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exponentially amplified by polymerase chain reaction.  A variety of methods can then be 
used to detect the presence of amplified DNA in samples.   
 Many swine focused laboratories can complete RT-PCR for same day the 
results.  The structural proteins coded for by open reading frame (ORF) 6 and 7 are 
typically targeted for detection as these regions of the genome are highly conserved.  
ORF 6 codes for the matrix protein (M) while ORF 7 codes for the nucleocapsid protein 
(N) [6, 7].  The benefits of PCR include: rapid detection of PRRS RNA, ability to 
quantify viral loads, high sensitivity, high specificity, ability to identify most 
heterologous isolates, and ability to test numerous diagnostic specimens (tissue 
homogenates, serum, and body fluids/secretions).  Oral fluid samples should be tested 
using RT-PCRs verified to function adequately in the oral fluid matrix for ensured 
results quality [8, 9].   
The disadvantages of PCR assays include: high sensitivity (relatively easy for 
contaminates to cause false positives), inability to identify some genetically diverse 
isolates (due to primer or probe mismatching), lack of uniform performance between 
laboratories, and inability to differentiate infectious from inactivated virus [10].  Pooling 
of serum, semen, blood swabs or tissue specimens is routinely performed in the field to 
reduce diagnostic cost, but does reduce the sensitivity of RT-PCR, especially when the 
prevalence of infection is low and samples contain relatively small viral quantities [9, 
11].   
 Currently, two commercial real-time reverse transcriptase-polymerase chain 
reaction assays are available in North America and other parts of the world (VetMax NA 
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and EU PRRS, Applied Biosystems, Foster City, California and VetAlert NA and EU 
PRRSV PCR, Tetracore, Rockville, Maryland) [12].  Both kits detect both type 1 
(European; EU) and type 2 (North American; NA) PRRSV isolates.  Samples are 
identified as positive when the amplification curve of DNA crosses the threshold limit 
(<37) for a positive sample.  The quantitative (qRT-PCR) assays give each positive 
sample a cycle threshold (Ct) value which is the cycle at which the curve crosses the 
threshold limit of detection.  Lower Ct values indicate higher levels of viral RNA in the 
sample.  Both assays have multiple primers and probes to detect a variety of isolates, but 
neither is perfect.  Of 423 clinical cases evaluated with both assays, 27 cases tested 
positive with one assay and negative for the other [12].   
 A recently developed multiplex assay includes primers and probes to detect and 
differentiate infection with type 1, type 2, and a highly pathogenic type 2 strain (HP-
PRRSV) with good sensitivity and specificity [13]. The HP-PRRSV strain emerged in 
China in 2006 and is characterized by high fever, morbidity, and mortality.  The 90 
nucleotide deletion in the nonstructural protein 2 (nsp2) coding region of HP-PRRSV 
serves as a marker to differentiate HP-PRRSV from other strains [14].  Additional 
differential molecular assays have also been described to differentiate HP-PRRSV from 
other type 2 isolates with the use of either a duplex real-time RT-PCR using minor 
groove binder probes or a SYBR Green-based RT-PCR [15, 16].  Similar strategies 
could be employed in the future to help differentiate infected from vaccinated animals if 
a differential modified live vaccine can be developed. 
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 Flinders Technology Associates (FTA) cards have been assessed for potential use 
as a transport medium for PRRS RT-PCR.  FTA cards contain a mixture of chemicals 
which lyse cells and inactivate bacterial and viral pathogens while preserving nucleic 
acids.  Samples held within FTA cards can be used for molecular diagnostics and can be 
shipped in standard letter mail envelopes at room temperature, which may facilitate 
testing in remote locations.  The cards are reported to be a safe, simple, and sensitive 
alternative method to transport serum, blood, and tissue samples for PRRSV RT-PCR.  
However, a significant decrease in sensitivity should be expected from oral fluid samples 
[17]. 
 The development of loop-mediated isothermal amplification (LAMP) reduces the 
need for advanced equipment necessary to perform PCR.  This technology allows 
amplification of DNA at a constant temperature in simple devices (water bath or heat 
block) and eliminates the need for expensive laboratory equipment such as thermal 
cyclers [10].  The amplified product is directly related to sample turbidity or a change of 
color when color indicator systems are used [18, 19].  This advance in technology does 
come with lower test sensitivity as compared to other RT-PCR assays, but may allow for 
additional production systems and veterinary clinics to perform more of their own in-
house testing for presence of PRRS virus [19].   
RT-PCR Interpretation 
 The individual kinetics of PRRS isolate replication varies significantly in vivo.  
In general, virus can be expected to be found at higher levels and for longer periods 
when naïve animals are infected [10].  Pig age also has an effect on viremia.  For both 
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virulent and attenuated PRRSV, peak viremia and duration were substantially greater 
than those in finishing pigs and mature adult animals [20].  Serum viral levels typically 
peak at 4-7 days post inoculation (DPI) before declining to undetectable levels by 29-35 
DPI in individual pigs while virus does persist longer in tonsil and lymph nodes than in 
serum, lung, and other specimens [figure 1] [10, 20].  RT-PCR can be used to identify 
PRRS RNA in infected pigs for up to 86 DPI in lymph nodes [21], 92 DPI in semen [4], 
[22], 105 DPI in oropharyngeal scrapings [23], and 251 DPI in serum and tonsil 
homogenates [24].  However, testing tonsils, oropharyngeal scrapings and lymph nodes 
generally has a poor success rate when beyond 90 DPI [10].  Oral fluid samples can be 
expected to be positive for 14-90 days after infection [25].  Individual oral fluid samples 
from boars were positive for at least 21 days [26].  Viral RNA can also be found with 
RT-PCR in most tissues from viremic live born piglets and occasionally in fetal thoracic 
fluid and tissues from mummies and stillborn piglets.   
The inability of RT-PCR to differentiate infectious from non-infectious virus is 
important to consider when interpreting test results.  Inactivated PRRS RNA is stable in 
solutions while the infectivity of virus has a half-life of approximately 6 days in cell 
culture medium [27].  Aerosolized virus maintains infectivity best at low temperatures 
and low humidity, with a peak of about 3 hours under experimental conditions [28].  
Differentiating infectious from inactivated virus is typically only important when 
evaluating environmental samples (transportation equipment, air samples, etc.). 
Interpretation of negative results may include: no viral nucleic acid present (pig 
not infected), inability of PCR primers or probes (real-time RT-PCR) to detect 
17 
 
genetically diverse isolates (present but not detected), degradation of virus due to poor 
sample quality, individual pig not currently infected despite a low prevalence of virus in 
population, and pig is infected but the tested specimen does not contain viral nucleic 
acid.  False negative results are a major concern with RT-PCR, as no assay is capable of 
detecting all field strains especially in regard to type 1 isolates [12, 29].  Coupling 
molecular testing strategies with antibody based techniques are recommended for 
surveillance of negative herds to increase the probability of detecting infection.  
Furthermore, determination of herd statuses with pooled samples tested via RT-PCR 
should be executed with caution as pooled samples can test negative, while individual 
samples may be positive.   
Interpretation of positive results includes the following scenarios: pig is viremic 
with infectious virus (vaccinated or wild type infection), inactivated virus recovered and 
amplified, and virus contamination from sample collection or testing process (false 
positive) due to high sensitivity.  All unexpected results should be immediately 
communicated to the laboratory for follow up testing and to alert diagnosticians of a 
potential need for assay improvement to recognize the continually mutating PRRS 
viruses [12, 30].   
Virus isolation (VI)  
 Virus isolation can be performed on any virus laden tissues (after 
homogenization) or fluids.  Samples should be chilled and held at (4°C) for less than 48 
hours due to the sensitivity of the virus to pH and temperature changes [27, 31-33] or 
frozen at -70°C for future testing.  For best results samples should be received at the 
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laboratory within 48 hours.  Virus isolation can be performed on Pulmonary Alveolar 
Macrophages (PAMs) or sublines (CL-2621, MARC-145) of the African Green Monkey 
kidney cell line (MA-104) [31, 34].  In addition to the established cell types used for in 
vitro growth, additional permissive cell types have been reported.  Several genetically 
modified cell lines have recently been developed to facilitate PRRSV replication in vitro 
including: immortalized PAM cells expressing the CD163 protein, immortalized porcine 
monomyeloid cells expressing the human telomerase reverse transcriptase, PK-15 cells 
expressing sialoadhesin protein,  and porcine, feline, and baby hamster kidney cells 
expressing the CD163 protein [35-38].  Other non-genetically modified cell lines have 
also been identified to support PRRSV replication in vitro.  St. Jude porcine lung (SJPL) 
epithelial cells are phenotypically distinct and react differently to PRRS infection as 
compared to MARC-145 cells [39].  Porcine endometrial endothelial (PEE) cells have 
also proven to be permissive to PRRSV replication in vitro and may provide future 
insights into associated reproductive disease pathogenesis [40]. 
The presence of Fc receptors on PAMs may account for their increased 
sensitivity for isolating virus in the presence of antibodies as compared to MA-104 cell 
types.  For optimum recovery of virus, VI should be performed on both PAMs and 
subline cell types as isolates vary significantly in their ability to replicate in each [41, 
42].  The pig source of PAMs is also important as those from Landrace breeds poorly 
support the growth of PRRSV in vitro [43].  MA-145 cells may preferentially favor 
replication of modified live vaccine viruses as MA-104 cells were used for in vitro cell 
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adaption.  Furthermore, it has been reported PAMs are required for the successful 
isolation of some European and European-like viruses [44, 45].  
The positive indicator for virus isolation, cytopathic effects (CPE), is not 
pathognomonic for PRRSV replication.  Therefore secondary confirmation steps can 
include: RT-PCR, negative-stain electron microscopy (EM), or visualization of viral 
antigens within cells by fluorescent antibody (FA) techniques using PRRS-specific 
monoclonal antibodies [46].  Lot to lot validation should be performed with samples 
known to contain specific concentrations of virus to verify results. 
VI Interpretation 
 Timelines to detect infection in vivo via VI are essentially the same as those 
described for RT-PCR, with the exception of having to wait 5-8 days for test results with 
the VI procedure versus potential same day results for RT-PCR.  Possible explanations 
for negative results from VI assay include: pig has not been infected, pig is infected but 
no infectious virus in sample (neutralizing antibodies/degradation of virus in sample), or 
pig is infected but virus is unable to infect cell culture line used.  For fetal samples, virus 
isolation is approximately half as sensitive as RT-PCR and is more prone to the negative 
effects of sample autolysis [5]. 
Antigen Labeled Microscopy (IHC and FA) 
 The typical gold standard for a pathological diagnosis is to correlate the 
suspected disease agent with identifiable tissue lesions.  Microscopic evaluation of fixed 
tissues allows for histopathological evaluation and the utilization of 
immunohistochemistry (IHC) techniques to visualize viral antigens within cells or 
20 
 
contiguous to microscopic lesions [47].  IHC can be performed on fresh and properly 
fixed (10% neutral buffered formalin) lung, tonsil, lymph nodes, heart, brain, thymus, 
spleen, and kidney [47-49].  Immunohistochemistry is reported to be highly specific 
(100%) and moderately sensitive (67%) [50].  Identification of PRRSV antigen in lung 
tissue by IHC has been found to require the examination of a minimum of five sections 
of anterioventral lung to identify >90% of PRRS infected pigs [49].  The highest 
sensitivity is appreciated when tissues are processed within 48 hours of fixation, which 
helps prevent antigen degradation and loss of positive cells [48].   
 If not feasible to get tissues into the laboratory promptly, antigen can also be 
detected in frozen lung sections by fluorescent antibody (FA) or indirect fluorescent 
antibody (IFA) techniques [31, 50, 51].  BAL fluid and cell cultures can also be analyzed 
by FA or IFA for detection/confirmation of PRRSV.  The FA test is quicker to perform 
and less expensive than IHC, but has the disadvantage of requiring fresh or frozen tissue.  
Both the IHC and FA tests require monoclonal antibodies to detect viral nucleocapsid 
antigen in the cytoplasm of infected cells and thus both tests may not detect genetically 
diverse isolates.  Both tests also rely on the laboratory operator’s ability to detect antigen 
and differentiate it from nonspecific background staining.  To increase test specificity, 
positive tests can be confirmed with VI and/or RT-PCR. 
IHC and FA Interpretation 
 Identification of virus using IHC is best in the early stages of infection (1-28 
DPI), limited in the mid stages of infection (30-70 DPI) and not recommended in the 
latter stages (> 90 DPI) due to low sensitivity [10].  IHC can identify vertically 
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transmitted virus in most tissues from infected live-born piglets.  Evaluation of BAL 
samples with FA can be performed directly (without first amplifying potential virus in 
cell culture) in the early stages of infection, directly or immediately after incubation in 
cell culture of lavage fluid in the mid stages of infection, and is not recommended in the 
latter stages of infection.  Evaluation of lungs from live-born piglets can also be 
successful with FA. 
Interpretation of negative samples may include the following scenarios: pig is not 
infected, pig is infected but has no virus in sections examined, operator is unable to 
identify antigen-antibody complexes, or pig is infected with a genetically diverse isolate 
not bound by monoclonal antibodies.  Positive FA results can either be due to true 
infection or due to the poor specificity of antibody used in the assay (false positive). 
Field Test Strips 
 The recent development of immunochromatographic test strips for the detection 
of PRRS virus has been described [52].  The strip tests have the benefits of speed, 
convenience, and requiring less technical skill or sophisticated laboratory equipment.  
The test is performed by adding serum or tissue homogenate to a mixture of gold-labeled 
monoclonal antibodies to the PRRSV N and M proteins.  If present, virus binds to the 
antibody and the antigen-antibody complexes are captured on chromatographic test 
strips.  Positive samples are detected using a labeled antibody which binds to the 
monoclonal antibodies.  Unbound monoclonal antibodies move past the test line and are 
captured by a separate set of monoclonal antibodies which produce a band representing a 
control line.  From trial work performed in China, a sensitivity of >93% and specificity 
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of >96% was reported when samples were compared to RT-PCR testing [53].  However, 
these assays are not currently commercially available in the USA. 
Test Strip Interpretation 
 Field test strips have not been widely used to date.  Caution should be taken 
when interpreting results in light of reported sensitivity and specificity data due to 
relative lack of diversity of viruses tested.  Positive results could be due to: true presence 
of virus, sample contamination, or result of poor specificity of monoclonal antibodies 
used in the test strip.  Negative results could be the result of: true negative specimens, 
positive animals not shedding virus currently, positive animals with no virus in tissue 
examined, inability of the test to identify low levels of virus, and inability of the 
monoclonal antibodies to identify genetically diverse isolates. 
Swine Bioassay 
 The swine bioassay is a variation of the third fulfillment of Koch’s postulates 
which states “the pathogen from a pure culture must cause disease when inoculated into 
a healthy susceptible animal.”  The swine bioassay was first described to evaluate semen 
for PRRSV, where 15 ml of whole semen is injected intraperitoneally into 4-8 week old 
PRRSV naïve pigs [4].  The inoculated pigs are placed in strict isolation and monitored 
weekly for seroconversion for a total of 5 weeks.  The bioassay is very laborious, 
requires additional use of animals for diagnostic purposes, and is very slow.  This assay 
is no longer of routine diagnostic value, but could be used with modifications if 
genetically diverse PRRS isolates surface in the future as it is the most sensitive 
diagnostic assay available to date to find live virus.   
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Bioassay Interpretation 
 The swine bioassay interpretation relies on the ability of the virus from the 
presumed positive animals to infect naïve pigs.  Potential causes of negative results 
include: no infectious virus present, virus is present in host but neutralizing antibodies 
prevent infection, or virus is present in host but absent/in low concentrations in sample.  
Positive results could be due to presence of infectious virus in sample, contamination of 
naïve pigs with a different strain or false positive reaction on the confirmatory test used 
on the sentinels. 
Electron Microscopy 
 Electron microscopy (EM) was used as an early diagnostic tool shortly after 
PRRS was first described.  Evaluation of virus isolated on PAMs with an electron 
microscope should reveal spherical, enveloped, 45-55 nm in diameter, virus particles 
with a 30-35 nm nucleocapsid [54].  Electron microscopy is not used for routine 
diagnostics due to the time constraints for testing, sophisticated equipment necessary, 
and requirement of specialized technologists.  However, similar to the swine bioassay it 
could have some utility if variant isolates emerge which can’t be recognized by current 
molecular or antibody based techniques. 
EM Interpretation 
 Interpretation of negative results could include the following: no virus present, 
viral particles present but morphologically unidentifiable, viral particles present but not 
in sufficient concentration to be identified by operator, or virus is present in host but 
unable to grow in cell culture medium used for amplification of virus. 
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Detection of Antibody 
Serology 
 Serology has historically been favored by swine practitioners because serum is 
easily collected in large quantities for multiple tests which are readily available.  Oral 
fluid samples and muscle transudate can now also be used to detect antibodies in pigs 
[55, 56].  The documentation of seroconversion using acute and convalescent samples is 
the definitive method to diagnose PRRS exposure.  Increasing titers of PRRS specific 
antibody provides good evidence for recent PRRSV exposure.  However, serology is not 
a valid approach for a diagnosis of PRRS in previously infected or vaccinated herds, 
because current serological assays cannot clearly differentiate among antibodies 
resulting from an initial infection, reinfection, or vaccination [10].  Single serum samples 
can be used to confirm exposure or vaccination compliance in previously naïve pigs, but 
cannot be used to prove PRRS is the clinical diagnosis.  The tests used to detect the 
presence of PRRS specific antibodies include: enzyme-linked immunosorbent assay 
(ELISA), indirect fluorescent assay (IFA), virus neutralization (VN), immunoperoxidase 
monolayer assay (IPMA), and immunochromographic test strips.  Multiple serological 
assays are often used for confirmation of questionable samples.  The three most 
commonly utilized serologic diagnostic tests include the ELISA, IFA, and VN assay.  To 
put the use of these tests in perspective, the Iowa State University Veterinary Diagnostic 
Laboratory ran the following serological tests for PRRSV in 2012: 146,560 HerdCheck® 
X3 PRRS ELISA, 7,658 HerdCheck® X3 PRRS ELISA for oral fluids, 2,977 indirect 
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fluorescent antibody tests (1,786 North American and 1,191 for European strains), and 
395 PRRS neutralization assays [57]. 
ELISA 
 The ELISA is the most commonly used serological test for detection of PRRS 
antibodies due to its sensitivity, specificity, speed, and reproducibility.  The commonly 
used commercial ELISA (HerdChek® X3 PRRS ELISA, IDEXX Laboratories, 
Westbrook ME) is considered the reference standard for the detection of antibodies to 
PRRSV [10].  This is an indirect ELISA which utilizes the N protein as the target 
antigen for both North American and European viral strains.  The N protein is the most 
abundant viral protein, is highly immunogenic, and induces an early antibody response 
in pigs [58].  Recombinant N protein is coated on plates, serum is added, and anti-
PRRSV antibodies are visualized with the addition of an anti-pig Horseradish 
Peroxidase-Conjugated Immunoglobulin G (IgG-HRP) conjugate as a second step 
(making this an indirect assay).  This test replaces the PRRS 2XR kits (IDEXX 
Laboratories) and offers significantly improved specificity (99.9%) while maintaining a 
high level of sensitivity (98.8%) [59].  Per kit instructions, results are expressed as a 
sample-to-positive (S:P) ratio, which is calculated by taking the optical density (OD) of 
a given sample on the PRRSV coated well minus the sample OD on the normal host cell 
(NHC) antigen coated well divided by the positive control OD on the PRRSV antigen 
coated well minus the positive control OD on the NHC coated well.  For the HerdChek® 
X3 PRRS ELISA S:P ratios  ≥ 0.4 are considered positive.   
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The HerdChek® X3 PRRS ELISA protocol can be adapted to the oral fluid 
matrix to calibrate the reactivity of the assay to the lower concentration of antibody 
present in oral fluids relative to serum.  Immunoglobulins M (IgM), IgA, and IgG can all 
be readily detected in oral fluid and from a population of animals.  The kinetics of each 
immunoglobulin in oral fluid are very similar to those found in serum, with the 
exception of IgA being identified quicker and for a longer duration in oral fluids [60].  
Furthermore, the PRRSV oral fluid ELISA has proven to have a high level of 
repeatability and reproducibility amongst laboratories [61].  Testing of oral fluids for 
antibodies using pen-based oral fluids is a non-technically demanding and cost-effective 
approach for monitoring commercial herds. 
 A double recognition (DR) ELISA (Ingezim PRRS DR, Inmunología y Genética 
Aplicada SA, Madrid, Spain) has recently been developed and is commercially available 
for detection of European isolate generated antibodies.  The principle of the DR-ELISA 
is based on the simultaneous binding of antibody sandwiched between precoated and 
enzyme-conjugated antigens [62].  Plates are coated with recombinant N protein, 
washed, serum (diluted with horseradish peroxidase-conjugated N protein) is added for 
one step incubation, and finally the reaction is revealed by addition of substrate and 
stopped prior to reading [63].  Per kit instructions, S:P ratios > 0.175 are considered 
positive.  The DR-ELISA has a reported specificity of 99% and drastically increased 
sensitivity for detecting antibody at 7 DPI (88% vs. 22% for HerdChek® X3 PRRS 
ELISA) [64].  The DR-ELISA is better suited to identify IgM due to the use of coated 
and conjugated antigen.  The pentameric conformation of IgM allows one antibody to 
27 
 
bind up to ten antigens as compared to IgG which is theoretically limited to binding two 
antigens.  The DR-ELISA performance beyond 21 DPI is reportedly very similar to the 
HerdChek® X3 PRRS ELISA [63].  The higher sensitivity for detection of early 
infection makes the DR-ELISA a more suitable test for naïve farms.   
  Other ELISA tests have been described, including CIVTEST Suis: PRRS which 
uses native proteins of Lelystad virus (EU prototype strain) for antigen (Laboratorios 
HIPRA, SA, Girona, Spain) and Ingezim PRRS Compac which utilizes an E.coli-
expressed nucleocapsid protein from a type 1 isolate as an antigen (Inmunología y 
Genética Aplicada SA, Madrid, Spain).  As well as the blocking ELISAs Bio-Vet PRRS-
Blocking which uses an E.coli-expressed nucleocapsid protein as an antigen (Bio-Vet 
Laboratories, Saint-Hyacinthe, Quebec) and Ingezim PRRS Europa/America/Universal 
which utilize viral proteins produced in E.coli as antigen (Inmunología y Genética 
Aplicada SA, Madrid, Spain). 
 Blocking ELISAs are performed by coating test plates with an antigen lysate as 
for the indirect ELISA.  Diluted test serum is then added and allowed to react with the 
test antigen if containing antigen specific antibodies.  After washing, specific enzyme-
labeled antibody directed against the test antigen is added, resulting in competition with 
the test serum antibodies.  Negative serum samples result in maximum color 
development, whereas samples with specific antibodies specific antibodies show less 
color development with increasing antibody. 
Numerous studies have shown nonstructural proteins 1, 2, and 7 also induce high 
levels of antibody during PRRSV infections [65-67].  An ELISA was developed with 
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nsp2 and nsp7 as the target antigens for pigs infected with both North American and 
European isolates.  The assay was positive 14 through 126 DPI.  The results using nsp2 
or nsp7 as target antigens correlated well with the commercial 2X ELISA kit.  
Furthermore, the nsp7 ELISA resolved 98% of samples with suspected false-positive 
results from the 2X ELISA and was able to differentiate type 1 versus type 2 infection in 
469 of 470 samples [67].  Therefore, these other antigen targets may have use as future 
commercial, confirmatory, or differentiating tests. 
Several differential ELISAs have been developed to distinguish viral exposure to 
PRRS isolates with nsp2 deletions from other isolates [68, 69].  An indirect ELISA to 
differentiate HP-PRRSV from other Chinese type-2 strains has been developed with 
reportedly good sensitivity and specificity [69].  This assay uses the lack of antibodies 
against the 30 amino acid deletion sequence within the nsp2 portion of the HP-PRRS 
genome as a target for differentiation.  A similar approach could be utilized to 
differentiate infected from vaccinated animals if a modified live vaccine with significant 
genomic changes from field strains can be developed in the future. 
ELISA Interpretation 
It is important to keep in mind the high degree of variation in individual animal 
immune responses and to use care not to over interpret the significance of differences 
between S:P ratios [44, 65, 70, 71].  These ratios are not generally considered a “titer” 
since it does not use a serial dilution of the serum to obtain a result that is 
immunologically meaningful [72].  The level of antibody also cannot be used as an 
indicator of isolate virulence [20].  ELISA samples collected at a single time point can 
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be difficult to interpret and should not be used to estimate the particular stage of 
infection [73].   
Maternally derived antibodies will persist for 3-5 weeks, while new infections 
will first become positive for IgM at 5-7 DPI and IgG 7-10 DPI [74-76].  Antibody 
levels typically peak at 30-50 DPI prior to declining to negative levels by ~ 300 DPI [10, 
77].  Antibodies in oral fluids have been detected for up to 126 DPI [60].  Oral fluids 
have also been found to detect exogenous PRRSV antibody in pigs fed diets including 
spray-dried porcine plasma [78].  If exogenous sources are suspected to be causing false 
positives, feed samples can be submitted and assayed for PRRSV antibody directly or 
serum samples can be tested since the feed antibodies are not expected to reach the 
serum intact.  Positive sample interpretations can include: exposure to PRRS virus or 
vaccine, detection of maternally derived antibodies, detection of exogenous antibody, or 
classification due to low specificity of the test (false positive).   
  Possible causes for negative samples can include: no exposure, pigs recently 
exposed but have not seroconverted (prior to day 7 of infection for DR-ELISA and day 9 
for HerdChek® X3 PRRS ELISA), pigs are harboring virus in lymphoid tissues yet have 
become seronegative, pigs have cleared the infection and reverted to seronegative, or 
pigs are negative due to low test sensitivity [79].  Persistently infected pigs which are 
negative by ELISA can be revealed through isolation of infectious virus or detection of 
viral RNA in tonsil, lymphoid tissues, or oropharyngeal scraping [23, 80].   
The impact of pooling samples should also be considered when evaluating test 
results.   Compared to testing samples individually, pooling serum samples to detect 
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antibodies results in a decreased sensitivity and increased specificity.  Reducing the S:P 
cutoff value recommended by the manufacturer has the opposite effect (increases 
sensitivity and decreases specificity).  A recommended protocol which increases herd 
level sensitivity and specificity compared to testing samples individually includes testing 
samples in pools of 2-10 and keeping the total number of tests the same [81].  However, 
this does result in increased sample collection costs as more samples are required. 
FMIA 
The fluorescent microsphere immunoassay (FMIA) uses multiple fluorescent 
microspheres for the simultaneous detection of multiple antibodies or antigens in 
biological samples.  These assays use multiple beads which each have a distinct dye to 
distinguish them from each other when using flow cytometry.  Individual beads can be 
conjugated to different antigens or antibody to capture specific molecules within a 
sample.  Samples are measured using the fluorescence of a secondary antibody if the 
target successfully binds with the bead.  The advantage of FMIA is the ability to detect 
multiple antigens or antibodies simultaneously with small sample volumes.   
The ability of FMIA to detect antibodies in oral fluids was evaluated due to the 
relatively low sensitivity of antibody detection in oral fluid samples when using 
traditional assays [82].  Recombinant nsp7 and N proteins of type 1 and 2 genotypes 
were coupled to microspheres.  Serum or oral fluid was combined with the antigen-
coupled microspheres and allowed to incubate to allow for antigen-antibody binding.  A 
secondary labeled antibody was then added as an indicator and the combination was 
again allowed to incubate.  The results showed the oral fluid-based FMIAs achieved 
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>92% sensitivity and 95% specificity while the serum samples had greater than 98% 
sensitivity and 95% specificity.  Antibodies against the N protein were more sensitive 
for the detection of early infection while the nsp7 directed antibodies were detected at 
higher concentrations and for a longer duration.  In serum the antibodies against both 
proteins were detected as early as day 7 and persisted for greater than 202 days [82].  
FMIA Interpretation 
 Interpretation of results for the FMIA assay is very similar to those for the 
ELISA.  The exceptions would be the FMIA is more sensitive for the detection of early 
infections as compared to the traditional ELISA. 
IFA 
The indirect fluorescent antibody (IFA) test is performed by placing serum onto 
virus-infected cells in microtiter plate wells, adding fluorescein-labeled anti-porcine 
antibodies, and then screening for antigen-antibody reactions with the use of a 
fluorescent microscope.  This procedure can provide relative antibody titers by using 
serial dilution of samples.  The IFA detects IgM and IgG antibodies.  The IFA generally 
has good specificity, but sensitivity is impacted by the technical skill of laboratory 
technicians, cell types used, laboratory protocol (media, incubation times, etc.) and 
antigenic differences between the PRRS isolate used in the IFA and the field virus 
inducing antibodies in the pig [44].  Typically, the IFA is used to confirm suspected 
false-positive ELISA results, but has also been used to detect PRRS antibodies in muscle 
transudate (meat juice) and oral fluid samples in surveillance programs [55, 56].  
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IFA Interpretation 
 The IFA is typically able to detect antibodies earlier in the infection stage than 
available commercial ELISAs.  An IFA can detect IgM as early at 5 DPI and IgG as 
early as 9-14 DPI [74].  The duration of antibody detection is slightly different than the 
ELISA as the IFA will detect IgM for 21-28 DPI and IgG for 90-145 DPI prior to going 
negative.  Peak IgG levels will be detected at 30-50 DPI, similar to ELISA.  Antibodies 
can be detected in piglet umbilical cord blood but typically only in those which are VI or 
RT-PCR positive [10].  
Potential scenarios for negative tests include: pigs not exposed, pigs recently 
exposed but have not seroconverted (prior to 5 DPI for IgM and 9 DPI for IgG), pigs are 
persistently infected (harboring virus in lymphoid tissues) and have become 
seronegative, pigs have cleared the infection and reverted to seronegative, pigs are 
negative due to low test sensitivity, pig was exposed to a genetically diverse isolate 
compared to the isolate used to in the test, or operator is unable to detect/differentiate 
antigen-antibody complex. 
VN 
 Virus neutralization assays detect antibody capable of neutralizing a given 
amount of PRRSV in cell culture.  A combination of sample serum dilutions and a 
constant amount of virus are incubated to allow any neutralizing antibodies present to 
bind to infectious virus.  After incubation, the mixture is then added to sensitive cells 
which are assessed for visible CPE 3-5 days later.  If no neutralizing antibody is present, 
CPE should be apparent.  However, in the presence of neutralizing antibodies, no CPE 
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will be apparent at lower serum dilutions and a titer can be determined where CPE 
becomes apparent.  Use of both PAMs and celllines are recommended due to the 
significant differences in the infectious process of the two cell types [83].  The VN test is 
highly specific, but has poor sensitivity.  VN tests have no standardized protocols or set 
of reagents to be used, and most laboratories have developed similar but independent 
systems [44].  VN assays are typically used only for research purposes due to its time-
consuming nature, technical difficulty, and cost to perform.   
VN Interpretation 
 Neutralizing antibodies have not been clearly linked to immunity or protection 
against virulent virus, thus the interpretation to clinical situations is difficult.  If the 
homologous virus is not used in the assay, results should be interpreted with caution due 
to the varying ability of neutralizing antibodies to bind heterologous virus.  Neutralizing 
antibodies have been identified as early as 11 DPI [84], but often do not develop until 
30-60 DPI, if at all [31].  Furthermore, some pigs develop relatively low levels of 
neutralizing antibody [58].  Neutralizing antibodies typically peak 60-90 DPI and persist 
for up to 365 DPI.  Possible explanations for negative VN assays include: pigs were not 
exposed, pigs were recently exposed but have not seroconverted (prior to 30 DPI), pigs 
are persistently infected and have become seronegative, pigs have cleared the infection 
and reverted to seronegative, or the isolate used in the assay is genetically diverse to the 
field isolate and unable to bind. 
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Field Test Strips 
 Similarly to the recent development of immunochromatographic test strips to 
detect viral antigen are lateral test strips to detect PRRSV specific antibodies.  This assay 
(Biosign™PRRSV) uses Escherichia coli-expressed viral N protein for detecting 
PRRSV specific antibodies in serum.  Strip test sensitivity and specificity were 
compared for serum from both clinical and experimentally infected pigs with a 
commercially available ELISA kit (HerdChek® PRRS ELISA).  The test was able to 
detect anti-PRRS antibodies with greater than 93% sensitivity and 98% specificity when 
compared to the commercial ELISA [85].  Another described lateral test strip uses 
recombinant N and M protein for the detection of anti-PRRS antibodies, reported a 
sensitivity and specificity of >97.8% when compared to the commercially available 
indirect ELISA (CIVTEST™ SUIS PRRS) kit [86].  Benefits of these tests include: no 
requirements for highly trained technicians or sophisticated laboratory equipment, speed, 
ability to store the kits at room temperature, and relatively low cost [85, 86].  Like other 
antibody assays these tests may not recognize genetically diverse antibodies.  These test 
kits are not commercially available in the USA currently, but could have utility for 
stakeholders. 
Test Strip Interpretation 
Similarly to the antigen detection field test strip, these tests have also not been 
widely used to date.  Caution should be used when interpreting results in light of 
reported sensitivity and specificity data due to relative lack of diversity of isolate based 
testing.  Positive results could be due to true presence of antibody or nonspecific 
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reactivity to target antigens on strip.  Negative results could be the result of: no pig 
exposure, recent exposure but inadequate time for seroconversion, pigs are persistently 
infected and have become seronegative, pigs have cleared the infection and reverted to 
seronegative, or pigs are negative due to inability to identify genetically diverse isolates. 
IPMA 
 The immunoperoxidase monolayer assay (IPMA) is very similar to the IFA, but 
utilizes a peroxidase-labeled secondary antibody and chromogen for color visualization 
of positive samples.  These assays can be read with a standard light microscope.  The 
IPMA was the first serological test reported for the diagnosis of PRRS [45].  This assay 
is sometimes used to differentiate between genotypes for ELISA positive samples [87].  
The IPMA has a high specificity and sensitivity, but is laborious to perform, requires 
sophisticated equipment, and can’t be automated for large-scale use [88].  The IPMA is 
mainly used in Europe while the similar IFA test  is most commonly used for PRRS 
diagnostics in North America [89].   
IPMA Interpretation 
The IPMA by design incorporates more potential epitopes for antibody binding 
than most ELISA tests which may improve detection of heterologous isolates.  However, 
the choice of virus used in the assay greatly affects the results and can lead to false 
negatives with very heterologous strains [87].  The IMPA can first detect PRRSV 
specific antibodies at 7-14 DPI [89].  IMPA based assays have identified IgA first in 
serum at 14 DPI and maximum concentrations at 25 DPI prior to declining to negative 
levels at 35 DPI [90]. 
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Isolate Characterization 
Often producers and veterinarians need more information than qualitative or 
quantitative results of presence of virus to facilitate management decisions such as 
moving animals onto another farm, tracking isolate spread, and determining if a new 
isolate is present in a population of pigs.   
RFLP 
The first technology which attempted to further characterize isolates came with 
the use of ORF 5 restriction fragment length polymorphism (RFLP) [91, 92].  This 
technology utilizes three different restriction enzymes (MluI, HincII, and SacII) to cut at 
specific sequences of nucleic acids.  Results are reported as a numerical code with the 
cut pattern of each respective enzyme [92].  Current known possibilities for the codes 
include:  4 possibilities for the first code, 96 possibilities for the second code, and 11 
possible different cut patterns for the third code [93].  For example, an isolate with a cut 
pattern report of 1-8-4 would have no cut sites for MluI (code 1), three specific cut sites 
for HincII (code 8), and four cut sites for SacII (code 4).  This technology was originally 
designed to differentiate vaccine virus from challenge viral strains [92].  However, it is 
increasingly being recognized as an insensitive method for characterizing genetic 
relatedness among viruses, as RFLP patterns unpredictably and inconsistently change 
through conversion and reversion during in vivo replication  [10, 94-96].  Theoretically, 
a single nucleotide change can alter the RFLP cut pattern without changing the 
pathogenicity, antigenicity, replication kinetics, or other clinically relevant viral 
characteristics. 
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RFLP Interpretation 
Isolate characterization by RFLP has limitations due to the relative amount of 
significant data they provide.  Many laboratories still report the expected RFLP patterns 
for isolates which underwent sequence analysis.  This information is provided as a result 
of frequent customer requests if such information is not provided with initial results.  
Sequence analysis 
 The use of sequencing and phylogenetic analysis is now widely available and 
provides a much more precise and accurate description of isolate genetic makeup by 
providing an exact genomic composition for the section examined.  Sequences are 
attained directly from PCR products of diagnostic samples to avoid potential bias of 
selection, mutation, or nucleotide changes by passage in cell culture [10]. Sequencing is 
typically only performed on ORF5 and may or may not include ORF6.  ORF5 has been 
identified as one of the most variable genes while ORF6 is the most conserved gene 
[97].  Sequencing of ORF5 allows for monitoring of herd level viral changes over time.  
To complete sequence analysis viral RNA must be intact and in sufficient quantity.  
Generally, sequencing requires more viral RNA than is necessary for RT-PCR and it is 
fairly common for a sample to be RT-PCR positive, but unable to be sequenced.  
Attaining genomic sequences from infected tissues and serum generally has good results, 
while oral fluids can be troublesome.  To optimize the ability to get sequence analysis 
from oral fluids, current recommendations are to freeze the samples and transfer to the 
laboratory immediately to preserve sample integrity [55]. 
38 
 
Sequences of ORF5 are highly variable and with the widespread use of PRRSV 
sequencing, there is now an extensive library of sequences available for comparison.  
Diagnostic laboratories typically provide the sequence analysis information in 
comparison to known modified-live vaccine strains for comparison to help differentiate 
wild type virus from vaccine isolates.  Dendrograms and identity matrices are additional 
tools which can help depict phylogenetic relationships based on isolate similarity to 
facilitate comparison of noteworthy isolates.  Laboratories can typically generate farm 
specific dendrograms upon request.  Dendrograms are created by aligning the nucleotide 
sequence or predicted amino acids sequence of a sample set in an ordered fashion 
according to the similarity of sequences.  Specialized computer programs evaluate all 
possible sequences and groups them accordingly with the end result being a 
phylogenetic tree (dendrogram).  The relationship of samples is based on all changes 
being the result of random, independent mutations during the natural evolution of the 
virus.  Dendrograms can help determine if the reappearance of PRRS on a farm is due to 
the introduction of a new strain or due to the reemergence of a strain previously 
identified.  Sequence analysis can’t be used to predict virulence of isolates or select the 
most efficacious vaccines due to the lack of information on genes responsible for 
pathogenesis and clinical immunity. 
Sequence Analysis Interpretation 
  Sequence analysis data is interpreted in light of evaluating relatively small 
amounts of genetic information (600-603bp for ORF5) in comparison to the entire 
genome (~15,000bp).  PRRSV sequence changes within 1% or less are consistent with 
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known amounts of changes over short periods of time (100-730 days), as defined by 
experimental studies [44, 98, 99].  A rate of change outside this range increases the 
likelihood of the isolates being unrelated.  Additionally, it is possible for a sample to 
contain more than 1 isolate.   
Dendrograms should be considered with caution, as it is important to consider the 
possibility of nonrandom mutations.  Recombination and genetic selection through 
immunological resistance have both been reported and would have a significant effect on 
the construction of a dendrogram and the conclusion of a whether a new virus is present 
within the herd [100-104]. 
2.4 Determine Sample Size  
Once the objective (detection vs. prevalence) is determined, target population is 
defined, and test is selected, the number of animals to sample needs to be determined.  
When the objective is to detect at least 1 positive sample from a population, the number 
of animals to sample depends on the number of animals in the group (may include a 
particular room, barn, or site), estimated prevalence of disease in the population (0% - 
50%) (any prevalence greater than 50% will require the same number of samples), 
confidence level of detection, in addition to test sensitivity and specificity [2, 105].  A 
recommended strategy for ongoing surveillance of breeding herds is to test a 
representative sample on a monthly basis to achieve a probability of detection of 95% 
[106].  When the objective is to detect infection, sampling does not need to be random, 
but can be directed to higher-prevalence groups.  Necessary sample sizes can be 
calculated with the use of spreadsheets, specialized computer programs, or through the 
40 
 
use of available tables (for which the calculations have already been completed) such as 
those included [tables 1 and 2].   
For example, 95 times out of 100, thirty random samples will contain at least one 
positive sample if the true prevalence is 10% or greater.  If the prevalence is reduced to 
5% sampling 60 animals randomly is required to detect 1 positive sample with a 95% 
confidence level.  For negative herds, to prove with 100% certainty the herd is truly 
negative, all animals would have to be sampled.  These tables assume 100% test 
sensitivity, which rarely occurs for any test. 
When the objective is to determine prevalence within a population similar criteria 
need to be defined and include: population size, expected disease prevalence, confidence 
level of detection, and accuracy of your prevalence estimation.  Estimating group 
prevalence is performed by picking a number between 0% - 100%.  Recommendations 
are to error towards 50% prevalence, as a 50% prevalence carries the greatest standard 
error of a proportion which decreases as the prevalence goes in either direction.  
Choosing a sample size closer to 50% will require more samples to be tested and result 
in the most accurate estimation of the true prevalence.  Likewise, the smaller the 
accuracy level the more samples are required which results in a more accurate final 
prevalence estimation  [105].  Sample sizes to estimate prevalence of disease can also be 
calculated with the use of spreadsheets, specialized computer programs, or through the 
use of tables.  For example, with an expected prevalence of 50%, an accuracy of 10%, 
confidence level of 95%, and a population of 2,000, 92 samples would be required to 
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estimate the prevalence of disease.  However, if the accuracy level is increased to 5%, 
the sample size jumps to 322. 
Tests with lower sensitivities can be overcome by testing more animals to attain a 
higher level of confidence in results, while tests with poor specificity should be avoided 
altogether.  To compensate for tests with imperfect sensitivity, take the calculated 
sample size and divide it by the actual or estimated sensitivity of the planned test.  If the 
samples are to be used for more than one test, divide by the test with the lowest reported 
sensitivity to adjust the necessary sample size [105]. 
2.5 Interpretation of All Available Test Results 
 Upon receipt of test results, it is important to evaluate each as a separate piece of 
evidence given each test’s inherent limitations discussed previously.  If multiple test 
results are available, all results should be considered to make a clinical diagnosis.  Over 
the course of infection, some tests will be positive while others will still be negative 
[figure 1].  Along with the individual animal variation, when testing populations, the 
infection dynamics of the entire population is likely not exactly the same.  Figures 1-3 
summarize the potential causes of each possible test outcome and describe the expected 
test outcome depending on state of infection at the time of sample collection.   
2.6 Classification of the Herd 
 The final piece to the diagnostic process is the selection of terminology to 
classify a population of animals.  Standardized terminology has been recommended to 
facilitate communication between veterinarians, swine producers, genetic companies, 
and other industry stakeholders [107].  The following guidelines are those which have 
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been proposed as minimum requirements for testing to classify herds and do not 
necessarily reflect the best approach to attain a diagnosis for a particular herd. 
Breeding herd classifications include: positive unstable, positive stable, positive 
stable and undergoing elimination, provisional negative, and negative [107].  PRRSV 
shedding status is classified as negative, uncertain, or positive.  An uncertain status is 
used when diagnostic data suggests a negative shedding status, but there is insufficient 
statistical power to generate enough confidence for the official negative status.  
Exposure status is classified as negative or positive.  The default status is positive 
unstable when herds have not been tested.  To be classified as undergoing elimination, 
herds must have initiated an elimination procedure which begins when the last 
seropositive breeding replacements are introduced or when the last intentional exposure 
occurs in the herd, whichever event occurs later.  Herd classification is based on both 
shedding and exposure status of the herd [107].     
 Recommended testing criteria for assessment of PRRSV shedding status of 
weaning-age pigs for inclusion into positive stable categories include: testing a minimum 
of 30 serum samples per testing event, pooling samples in groups of 5 (if pooling), 
testing a minimum of 4 times to account for variation in prevalence, and not more 
frequent than every 30 days to confirm status.  If a herd has no positive samples over a 
90 day period or after completion of 4 consecutive negative herd tests (if sampling every 
30 days) and with no clinical signs in the breeding herd, then the herd can be 
appropriately classified into a positive stable category [107]. 
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Growing pig population categories are more straightforward with only positive 
and negative categories.  Negative populations must have no positive ELISA tests from 
30 submitted samples taken from multiple age groups if present and have no clinical 
signs consistent with PRRSV infection.  All other populations are classified as positive, 
including: those with positive ELISA tests, clinical signs consistent with PRRS, and 
herds without sufficient diagnostics [107]. 
3. Conclusion 
The diagnostic approach for Porcine Reproductive and Respiratory Syndrome 
virus is a complicated process.  The nature of the virus, dynamics of pig flow 
management, variety of control measures utilized in the field, and the continually 
evolving available technologies for testing make PRRS control and prevention strategies 
difficult.  However, routine surveillance and disease diagnostics are an essential 
component to successful control and elimination programs [108].   
Available tests have improved significantly over the years, but no available test is 
perfect.  The possibility of false positive and negative results should always be 
considered.  If results are different from those expected, additional testing should be 
requested if necessary for the clinical case.  Molecular techniques are capable of 
detecting viral RNA from a growing list of specimens which also allow for evaluation of 
viral epidemiology through sequencing.  Antigen detection techniques can be utilized to 
confirm virus in cell cultures or clinical samples and to correlate the presence of virus 
with pathological lesions.  Serological approaches are used to detect previous exposure 
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to virus and also can be performed on a growing list of more conveniently collected 
sample types.   
It is vital for veterinarians and stakeholders to have an understanding of the 
diagnostic approach to PRRS which includes determination of: diagnostic objective, 
population to test, appropriate test, required sample size, test results, and herd status.  
Test selection and interpretation of results are vital components towards the ongoing 
success of pork production within PRRSV endemic regions.  PRRS will likely remain a 
difficult problem to solve for producers, especially with limited knowledge of 
pathogenesis and imperfect tools to prevent and manage infections.  However, having a 
thorough understanding of PRRSV diagnostic procedures is undoubtedly an important 
part of the equation. 
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Table 1.  Sample Size to Detect at Least One Positive Sample from Herd [105] 
 
 
 
 
 
Table 2.  Sample Size Required to Estimate Prevalence Where the Expected True 
Prevalence is 50%. [105] 
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Table 3.  Criteria Required for PRRS Status Categorization of Breeding Herds 
[107]. 
 
Category Shedding 
Status 
Exposure 
Status 
Clinical 
Signs 
Evidence Required 
I Positive 
Unstable 
Positive Positive Current 
clinical 
outbreak 
Chronically recurring viral 
shedding 
II-A  
Positive 
Stable 
Uncertain Positive No clinical 
signs 
> 90 days of PCR (-) weaning 
age and growing pigs if present 
(> 4 consecutive PCR (-) tests, 
30 days apart or sooner 
II-B  
Positive 
Stable 
(Undergoing 
Elimination) 
Uncertain Positive No clinical 
signs, 
elimination 
program 
started 
> 90 days of PCR(-) weaning 
age and growing pigs if present 
(> 4 consecutive PCR (-) tests, 
30 days apart or sooner 
III 
Provisional 
Negative 
Negative Positive No clinical 
signs, herd 
rollover 
started 
> 60 days after the initial 
introduction of ELISA (-) 
breeding replacements with 
proof of maintained (-) exposure 
status 
IV Negative Negative Negative 
(new premise 
startup or 
total 
depop/repop) 
No clinical 
signs 
>  365 days of No ELISA (+) 
adult breeding animals after the 
category III status 
or 
> 30 days of no ELISA (+) after 
complete population with 
negative replacements 
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Figure 1.  Guidelines for PRRS Antigen and Serological Test Selection and 
Interpretation in Accordance with Natural Progression of Infection. 
 
 
1
Adapted and expanded upon from [109] 
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Figure 2.  Detection of Virus: PRRS Diagnostic Decision Tree 
 
 
Detection of Virus
Infectious virus present (vaccine or wt  strain)
Positive Noninfectious virus present
Sample contamination, no virus in pig
PCR
No viral RNA present
Inability to detect low levels of virus present
Negative Sample degradation, unable to detect virus in sample
Primer/probe mismatch, unable to detect virus in sample
No viral RNA in sample, but pig is persistently infection
No viral RNA in sample, but low prevalence of virus in herd
Positive Infectious PRRSv virus present
CPE present, but no infectious PRRS in sample
VI Infectious virus not present
PRRS isolate not capable of replicating in cell line used
Negative Infectious virus present, but bound with neutralizing antibody
Sample degraded, virus unable to replicate
Technician unable to identify CPE
Positive PRRS antigen in tissue
Poor specificity of monoclonal antibodies, no PRRS antigen in tissue
IHC No antigen in tissues
Pig acutely viremic with insufficient time to deposit antigen in tissue
Negative No antigen in tissue section examined, but antigen present in tissue
Operator unable to identify antigen present in tissue
Monoclonal antibodies unable to bind heterologous isolate present in tissue
Positive PRRS antigen identified
FA Poor specificity of monoclonal antibodies, no PRRS antigen in sample
No antigen in sample
Pig acutely viremic with insufficient time to deposit antigen in sample
Negative No antigen in sample section examined, but antigen present in sample
Operator unable to identify antigen present in sample
Monoclonal antibodies unable to bind heterologous isolate present in sample
Viral antigens present in sample
Positive Sample contamination
Non-specific binding of monoclonal antibodies, no PRRS viral antigens present
Test Stips
No viral antigens present in sample
Negative No viral antigens in sample, but positive pig
Viral antigens present in low quantity
Inability to identify antigens from heterologous isolates
Positive Infectious virus present
Contamination of susceptible pigs with a different strain of PRRS
Swine Bioassay
No infectious virus present
Negative Virus present, but bound by host neutralizing antibodies
Virus present in host, but absent/low quantity in naïve pig inoculum
Positive PRRS particles present
Particles identified with similar size, shape, and morphology
EM
No particles present
Negative Particles present, but morphologically unidentifiable
Particles present, but below threshold of identification
Virus present in host, but  isolate not capable of replicating in cell culture used
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1
Adapted and expanded upon from [72] 
Figure 3.  Detection of Antibody: PRRS Diagnostic Decision Tree 
 
 
1
Adapted and expanded upon from [72] 
Test Result Potential Cause
Detection of Antibody
Exposure to PRRSv (vaccine or wt  virus)
Positive Detection of maternally derived antibodies (persist for 3-5 wks), no PRRSv exposure
Non-specific antibody binding to antigens on plate, no PRRSv exposure
Detection of exogenous sources of PRRSv antibody (oral fluid only), no exposure
ELISA
No exposure to PRRSv
Recent exposure to PRRSv, but no antibodies developed yet (<9 DPI)
Negative Inability to detect low quantity of antibodies 
Infection cleared, now seronegative
Persistently infected pig, now seronegative
Inability to detect antibodies against very heterologous isolates
Exposure to PRRSv (vaccine or wt  virus)
Positive Detection of maternally derived antibodies, no PRRSv exposure
Non-specific antibody binding to antigens on plate, no PRRSv exposure
IFA
No exposure to PRRSv
Recent exposure to PRRSv, but no antibodies developed yet (<5 DPI (IgM) & <9 DPI (IgG))
Negative Inability to detect low quantity of antibodies 
Exposure to a heterologous isolate of PRRS as compared to isolate used in test
Infection cleared, now seronegative
Persistently infected pig, now seronegative
Positive Neutralizing antibodies present
Loss of assay viral infectivitiy 
VN No exposure to PRRSv
Inability to neutralize heterologous isolate used in test
Negative Exposure to PRRSv, but insufficient time to develop neutralizing antibodies (<11 DPI))
Inability to identify quantity of neutralizing antibodies
Infection cleared, now seronegative
Persistently infected pig, now seronegative
Positive Exposure to PRRSv (vaccine or wt  virus)
Non-specific antibody binding to antigens on strip, no PRRSv exposure
Test Stips
No exposure to PRRSv
Exposure to PRRSv, but insufficient time to develop antibodies
Negative Inability to identify quantity of neutralizing antibodies
Infection cleared, now seronegative
Persistently infected pig, now seronegative
Inability to identify heterologous antibodies against heterologous isolates
Exposure to PRRSv (vaccine or wt  virus)
Positive Detection of maternally derived antibodies, no PRRSv exposure
Non-specific antibody binding to antigens on plate, no PRRSv exposure
IPMA
No exposure to PRRSv
Recent exposure to PRRSv, but no antibodies developed yet (<5 DPI (IgM) & <9 DPI (IgG))
Negative Inability to detect low quantity of antibodies 
Exposure to a heterologous isolate of PRRS as compared to isolate used in test
Infection cleared, now seronegative
Persistently infected pig, now seronegative
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and Kay S. Faaberg 
 
Abstract 
The vaccine efficacy of six PRRSV Type 2 infectious clones, including five 
chimeras and a strain-specific deletion mutant, were examined using a respiratory 
challenge model in growing swine. The chimeras were constructed from different 
combinations of a licensed modified live vaccine (Ingelvac
®
 PRRS MLV) and a virulent 
field isolate (wt MN184) which differ by 14.3% on a nucleotide basis, while the deletion 
mutant tested had a broad deletion in the nsp2 region of strain MN184. The appearance 
of antibodies and virus characterization revealed regions of the genome that could 
influence PRRSV replication in vivo. Swine growth, clinical signs and lung lesions were 
also monitored. Average daily weight gain was negatively and directly impacted by 
some vaccines, and after challenge, vaccination with different constructs led to variable 
weight gain. We determined that 3 of the tested chimeras, including two previously 
published chimeras [1] and one in which strain MN184 ORF5-6 was placed on the 
background of Ingelvac
®
 PRRS MLV were able to prevent lung consolidation to a 
similar extent as traditionally prepared cell-passaged attenuated vaccines. The study 
suggested that only specific chimeras can attenuate clinical signs in swine and that 
attenuation cannot be directly linked to primary virus replication. Additionally, the strain 
MN184 deletion mutant was not found to have been sufficiently attenuated nor 
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efficacious against heterologous challenge with strain JA-142. 
1. Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSV) emerged to cause 
clinical problems in animals in the early 1990s on separate continents [2, 3]. Since then, 
the virus has spread to most swine producing regions of the world. PRRSV has been 
found to vary as much as 40% in nucleotide sequence and has been separated into two 
genotypes, European (Type 1) and North American (Type 2), based upon their original 
isolation location and date. As a result of this overwhelming diversity, the swine immune 
response is often not cross protective. PRRSV also induces a poor immune response in 
most animals. This incomplete protection appears to be due to several factors including 
the nature of the virus, the genetics of swine host and the complication of co-infection 
with other pathogens [4, 5]. One traditional method of vaccine preparation, culturing the 
virus over several in vitro cell passages in order to attenuate clinical symptoms, has 
resulted in several available products for use in the field [6, 7]. However, this can lead to 
incomplete protection against heterologous PRRSV strains and an uncertainty in 
selection of the appropriate vaccine for routine use [5]. A newer approach has been to 
evaluate infectious cDNA clones of PRRSV, which can represent chimeras or site-
specific changes that may potentially increase the immune response, and may also have 
specifically engineered deletions and/or insertions to provide markers for vaccine 
identification [1, 8-16].  
Limited reports using this new approach have suggested that specific PRRSV 
chimeras can provide direct attenuation of clinical signs in either a respiratory model or 
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a reproductive failure model [1, 10]. Our previous studies have demonstrated that two 
reciprocal chimeras (rMLVORF1/MN184 and rMN184ORF1/MLV) of Type 2 PRRSV 
strains, Ingelvac
®
 PRRS MLV and wild-type (wt) isolate MN184, could attenuate 
clinical signs of young swine after heterologous challenge with PRRSV strain SDSU73 
in a respiratory challenge model [1]. Therefore, it was hypothesized that additional 
chimeras created from the same parent strains, but with different regions of the genome 
exchanged, would be more efficacious in the face of virulent challenge than 
commercially available products and perhaps provide an alternate method of PRRSV 
attenuation. 
To extend these original studies, we examined the two original [1] as well as 
three additional chimeras, plus a deletion mutant recombinant of wt strain MN184, under 
different challenge conditions. The new genomic areas of study were chosen to consider 
the contributions of key regions of a virulent strain in inducing protection against 
subsequent heterotypic virus exposure. PRRSV ORF5-6 code for the major viral 
attachment domain, ORF7 encodes the nucleocapsid protein that surrounds the genome 
and interacts with the structural proteins in the virion, and the 3'UTR is critical to 
successful transcription of subgenomic RNAs and replication [17, 18]. The additional 
chimeras were synthesized using an Ingelvac
®
 PRRS MLV backbone. In addition, the 
replicase region known as nonstructural protein 2 (nsp2) has been shown to be 
immunogenic, contains hypervariable segments, encodes a protease responsible for 
replicase cleavage and harbors B-cell epitopes [12, 19-25]. Thus, in order to examine a 
possible role for nsp2 in protection, recombinant strain MN184 was modified by 
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removing 618 bases of the nsp2 coding region. The six engineered viruses were used as 
vaccines in parallel with two conventionally attenuated PRRSV strains, Ingelvac
®
 PRRS 
MLV and newly prepared MN184 (MN184-P102). The vaccinated animals were then 
challenged with wt Type 2 strain JA-142. The appearance of antibodies and virus 
characterization were followed over the course of the study. The results of these assays 
revealed regions of the genome that influence PRRSV replication in vivo. Swine growth, 
clinical signs and lung lesions were also monitored. Average daily weight gain was 
negatively and directly impacted by some vaccines, and after challenge, vaccination with 
different constructs led to variable weight gain. We also found that only the original 
chimeras and the one in which strain MN184 ORF5-6 was placed on the background of 
Ingelvac
®
 PRRS MLV were able to prevent lung consolidation after strain JA142 
challenge to a similar extent as the cell-passaged attenuated vaccines. The outcomes of 
this study suggested that only specific chimeras can attenuate clinical signs in swine and 
that attenuation cannot be directly linked to primary virus replication. Additionally, a 
large deletion in the nsp2 region of strain MN184 was not sufficient to reduce the 
pathogenicity of that strain, or serve as an adequate vaccine against heterologous 
challenge with strain JA-142. 
2. Materials and methods 
2.1. Cells and Viruses 
MA-104 cells (ATCC CRL2621) or MARC-145 cells, both African Green 
monkey kidney cell lines which support the growth of PRRSV, were cultured in 
minimum essential medium (EMEM, SAFC Biosciences M56416) with 10% fetal 
66 
 
bovine serum (Invitrogen) at 37°C, 5% CO2. PRRSV vaccine Ingelvac
®
 PRRS MLV and 
wt isolate MN184 were previously described [1, 26]. Two recombinant viruses, rMLV 
and rMN184, and two chimeric viruses, rMLVORF1/MN184 and rMN184ORF1/MLV, 
were rescued from cDNA clones (GenBank EF484031-EF484034) described previously 
[1]. Other recombinant viruses were generated as described below. MN184-P102 was 
prepared by successive passages of MN184C (GenBank EF488739) on MARC-145 cells 
at Boehringer Ingelheim Vetmedica, Incorporated. PRRSV strain JA-142 (AY424271) 
was used as a heterologous challenge virus for the swine studies and has also been 
characterized previously [27, 28].  
2.2. Construction of PRRSV cDNA Clones 
Different sections of pMLV were replaced with comparable sections of pMN184 
using specific restriction enzyme sites (Fig. 1) or the primers listed in Table 1. The 
correct nucleotides of the exchanged regions of every clone were confirmed by DNA 
sequencing. The nucleotide and amino acid changes as a result of the cloning are listed 
in Table 2.  
pMLV/MN184ORF5-6 (GenBank Accession FJ629369) possessed nucleotides 
(nt) 1-13650 and 14823-15452 of pMLV; nt 13651-14822 were exchanged for pMN184 
13257-14429 by PciI and SmaI restriction digest of subclone IV of each full-length 
plasmid (Fig. 1). pMLV/MN184ORF7-3’UTR (GenBank Accession FJ629370) 
consisted of nt 1-14822 of pMLV; nt 14823-15452 were replaced by pMN184 14430-
15060 by SmaI digestion of subclone IV of each full-length plasmid. In both constructs, 
the new subclone IV replaced its counterpart in pMLV. The specific regions targeted 
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span nucleotides 13,789-14,391 (ORF5), 14,376-14,900 (ORF6) and 14,890-15,452 
(ORF7 and 3'UTR) of the parental virus, Ingelvac
®
 PRRS MLV. 
pMLV/MN184-3’UTR (GenBank Accession FJ629371) was obtained in the 
following manner. One PCR product was amplified using pMLV and primer pair MLV-
ORF6-F/MLV-ORF7-R and another product representing the 3'UTR of MN184 was 
amplified from pMN184 using 184-3′UTR-F/184-3′UTR-R. Overlapping PCR was then 
completed with both PCR products and MLV-ORF6-F/184-3′UTR-R. The PCR product 
was then digested with SmaI and PacI and cloned into subclone IV of pMLV, which was 
then used to replace part IV in pMLV. The final pMLV/MN1843’UTR construct 
possessed nucleotides nt 1-15261 of MLV with only the 3’UTR (15262-15452) replaced 
with 14869-15058 of pMN184. 
As reported, wt strain MN184 has a tripartite deletion totaling 393 bases in the 
nsp2 region when compared to other sequenced viruses [20]. It was of interest to assess 
additional nucleotide deletions in regards to MN184 strain virulence reduction and the 
capacity of the mutated virus to protect against strain JA-142 challenge. One PCR 
product was amplified using pMN184 and primer pair 184-3122-F/184-4083-R, which 
was then digested with XhoI and AgeI, cloned into subclone II of pMN184 and then into 
a full-length viral plasmid. As a result, a 618 nucleotide segment of nonstructural protein 
2 (nt 2504-3121) was removed from pMN184 to produce the final pMN184Δ618 
construct (14, 440 bp; GenBank Accession FJ629372).  
2.3. Rescue of Viruses 
The cDNA clones were linearized with PacI and then transcribed in vitro 
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(mMessage Machine Kit, Applied Biosystems). RNA transcripts (2.5 g) of each clone 
were subsequently transfected into confluent MA-104 cells using DMRIE-C 
(Invitrogen), as described previously [1]. The transfection supernatants were collected 
when cytopathic effect (CPE) was approximately 80% and cell debris was then removed 
by centrifugation at 4000 x g. Recombinant viruses were passaged on MA-104 cells a 
total of 4 times to yield viral stocks sufficient in volume and titer to allow for 
vaccination studies. The rescued viruses were named rMLV/MN184ORF5-6, 
rMLV/MN184ORF7-3’UTR, rMLV/MN184-3’UTR and rMN184Δ618. Total RNA was 
extracted from an aliquot of passage 4 supernatant of each rescued virus and analyzed by 
RT-PCR followed by 3’ end sequencing of approximately 4000 bases.  
2.4. Swine Study 
The study utilized 100, healthy 3-week old, commercial crossbred piglets from a 
PRRSV seronegative herd to examine PRRSV vaccine efficacy in a respiratory 
challenge model. Animals were housed in a conventional setting at Veterinary Resources 
Inc. in Ames, Iowa and were under the supervision of a veterinarian. Throughout the 
duration of the study, all animals received food and water ad libitum. All laboratory 
personnel and animal caretakers involved with the study were blinded to the treatments 
given to the respective groups.  
The study consisted of 10 groups, including 6 infectious clones (groups 1-6), wt 
MN184 at passage 102 (MN184-P102; group 7), Ingelvac
®
 PRRS MLV (group 8), 
heterologous challenge virus wt JA-142 (group 9), and a strict control group (group 10) 
(Table 3). Animals were required to test negative for PRRSV antibody by HerdChek
®
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PRRS ELISA 2XR and then randomly assigned by weight into each treatment group 
prior to vaccination (IDEXX Laboratories Inc., Westbrook, ME). Viral titers were 
determined by TCID50/ml (Table 3) [29, 30]. All viruses were diluted with minimum 
essential medium (MEM; Sigma, St. Louis, MO.) containing 2% fetal bovine serum 
(FBS) (Sigma, St. Louis, MO.) in order to deliver a target of 4.79 logs of virus in 2 ml, 
intramuscularly, to each animal. The challenge control (group 9) and strict control 
(group 10) groups received only dilution medium. For testing purposes, 10 – 15 ml of 
blood was collected from each animal on Days 0, 3, 7, 14, 21, 28, 31, and 35. Serum was 
separated from the clotted blood and stored for a maximum of 24 hours at 4°C for 
testing. Aliquots were then frozen at -70°C. 
The challenge model used in this study is consistent with the model used in the 
original characterization of the chimeras [1]. This model calls for virulent challenge 
three weeks after vaccination (Day 21) and necropsy at five weeks post-vaccination 
(Day 35). Challenge timing was chosen since the vaccine component of the chimeras, 
Ingelvac
®
 PRRS MLV, has proven to be efficacious three weeks post-vaccination even 
though the vaccine virus may still be causing some viremia [31]. Therefore, it was 
expected that the chimeras would exhibit similar characteristics. Necropsy at two weeks 
post challenge allowed for maximal detection of lung lesions that correlate with in vitro 
testing procedures [32]. The animals in groups 1-9 were challenged intranasally with 3.8 
logs in 2 ml (1ml per nostril) of virulent JA-142 strain of PRRSV at cell passage 4. At 
necropsy all animals were humanely euthanized and assessed for gross lung lesions.  
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2.5. Clinical Evaluation 
General observations of each animal in the study were taken from Day 0 through 
Day 19 and anything abnormal was noted. From Day 20 through Day 35, clinical 
observations were noted and anything considered abnormal was recorded. Individual 
observations consisting of behavior, respiration, and cough were also recorded based on 
a numerical index from 1 to 4 that reflected the severity of the diseased state for each 
category. For instance, a normal animal received a score of 3 (3 x 1 each for behavior, 
respiration and cough), an animal exhibiting maximum clinical signs received a 9 (3 x 
3), and a deceased animal received a cumulative score of 12 (3 x 4). In addition, animals 
were weighed 3 days before vaccination (Day -3), at challenge (Day 21), and at necropsy 
(Day 35) for average daily weight gain testing. The lungs of all animals in the study 
were evaluated at necropsy for percent consolidation due to PRRSV infection. Lungs 
were scored for each individual lobe, as well as an overall level of gross lung pathology 
using a standard scoring system [33]. The observation score equaled the sum of all the 
individual lobe scores.  
2.6. Serology 
Serum samples were analyzed for PRRSV antibody using the IDEXX 
HerdCheck
®
 PRRS ELISA 2XR. The tests were performed as described by the 
manufacturer’s instructions. Samples were considered positive for PRRSV antibodies if 
the sample-to-positive (S/P) ratio was at least 0.4.  
2.7. Viremia Detection by Virus Isolation and Quantitative RT-PCR 
To qualitatively determine viremia, virus isolation was performed on all serum 
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samples from all collection days. Each animal was tested by inoculating 100μl of serum 
individually onto 3 day old MA-104 cells in a 48-well tissue culture plate which was 
then evaluated 8 days later for signs of cytopathic effect. The percent of positive animals 
at each bleed date was then recorded. To attain a relative quantity of viral RNA present, 
quantitative RT-PCR (qRT-PCR) was also performed on all serum samples. The 
QIAamp
®
 Virus BioRobot
®
 MDx Kit was used in conjunction with the BioRobot 
Universal System from Qiagen (Qiagen Inc., Valencia, CA) to extract the viral RNA 
from the serum per manufacturers recommendations. To detect US PRRSV nucleic acid, 
the North American Tetracore qRT-PCR kit (Tetracore, Inc., Rockville, MD) was used 
as described previously [29]. 
2.8. Nucleotide Sequence Analysis 
 Viral RNA was extracted from serum samples from each animal at day 21. To 
obtain a consensus nucleotide sequence of the structural genes at this time point, RNA 
extracts were pooled for each group and submitted for nucleotide sequence 
determination (oligonucleotide primers available on request). Sequences were analyzed 
using Geneious Pro Version 4.7.5 (Biomatters Limited). Approximately 4500 bases were 
sequenced at the 3'end of the viral genome. In the case of the nsp2 deletion mutant, 
rMN184Δ618, a 500 base section spanning the deletion site was examined. 
2.9. Statistics/biometrics 
All data were imported into SAS version 9.1 for management and preliminary 
analysis. Data listings and summary statistics by treatment group including mean, 
median, standard deviation, standard error, range, 95 percent confidence limits, 
72 
 
coefficient of variation, and frequency distributions were generated for all variables 
where appropriate. All parameters were compared among groups 1 – 9 and pair wise 
between groups 1 – 9. Group 10 (strict controls) was not included in the analyses other 
than summary statistics. In compliance with the methods recommended by the United 
States Department of Agriculture Animal Plant Health Inspection Service, only two-
sided results were reported and all comparisons were at α=0.05. All data were 
transferred to Prism 4 (Graphpad Software, Inc.) for additional statistical analyses and 
optimal formatting prior to publication. Virus isolation data used Fisher’s exact test to 
determine the number of animals positive/negative per group ratio. Weights and average 
daily weight gain (ADWG) were tested by two-way analysis of variance (ANOVA). 
Lung scores for each group were analyzed by one-way ANOVA and Bonferroni’s 
Multiple Comparison Test (95% confidence interval).  
3. Results 
3.1. Recovery of Viruses 
Two chimeric viruses, rMLVORF1/MN184 and pMN184ORF1/MLV, were 
previously generated [1]. Four other recombinant PRRSV full-length cDNA clones, 
pMLV/MN184ORF5-6, pMLV/rMN184ORF7-3’UTR, pMLV/MN184-3’UTR and 
pMN184Δ618 were constructed in a similar manner (Fig. 1). To verify whether these 
four additional cDNA clones were infectious, linearized pMLV/MN184ORF5-6, 
pMLV/rMN184ORF7-3’UTR, pMLV/MN184-3’UTR and rMN184Δ618 were 
transcribed in vitro and the synthetic RNAs were subsequently transfected into MA-104 
cells. Day 3 post-transfection, all four transfections resulted in the appearance of CPE, 
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indicating that the genetic exchange between the two different strains and the 618 base 
deletion in the nsp2 region of MN184 did not have a severe effect on the in vitro growth 
properties of the recombinants. Sequence analyses of around 4000 bases at the 3'-end of 
the genome confirmed that these four viruses were recovered from the respective 
recombinant PRRSV with no or a few scattered changes (data not shown). All chimeras 
were passaged 4 times on MA-104 cells in parallel with parental rMLV and rMN184 as 
well as Ingelvac
®
 PRRS MLV vaccine and wt MN184. At each passage, onset of CPE in 
rMLV/MN184ORF5-6 and rMLV/MN184-3’UTR infected MA-104 cells was similar to 
those infected with rMLV, but appeared 1 day later for rMLV/MN184ORF7-3’UTR 
infected cells. CPE for rMN184Δ618 infected cells was similar to rMN184 at all four 
passages. Passage 4 viruses were titered and used to infect 10 animals/group in the 
vaccination study (Table 3). 
3.2. HerdChek ELISA 
After vaccination, all animals in Groups 1, 2, 3, 5, 7, and 8 tested positive by 
IDEXX PRRS ELISA prior to strain JA-142 virulent challenge (Day 21). Group 6 
(rMN184Δ618) had 9 positive animals prior to challenge while Group 4 
(rMLV/MN184ORF7-3’UTR) had only 4 positive animals and the appearance of the 
antibodies in this latter group was delayed (Fig. 2 and data not shown). Antibodies 
appeared in Group 1 animals 3 days prior to all other vaccination groups. In addition, the 
S/P ratios suggested that all of the animals in groups 1 – 9 seroconverted to either their 
respective vaccine or the challenge material by Day 31 of the study. The Strict Control 
(group 10) had no positive tests throughout the duration of the study. Figure 2 indicates 
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the day when the individual groups became positive for PRRSV specific antibodies and 
the trend for all treatment groups. 
3.3. Virus Isolation 
Virus isolation analysis confirmed that at least 3 of the 10 animals in each 
treatment group were viremic by Day 3 in groups 1, 2, 3, 5, 7, and 8 (Fig. 3). Only 
(10%) of the animals in Group 4 were positive on Days 3 and 14, the only positive 
results obtained for rMN184ORF7-3’UTR prior to challenge. No viremia was detected 
for Group 6 (rMN184Δ618) animals until Days 14 and 21, which then showed positive 
results for only 10% and 20% of the animals, respectively. The results suggested that 
each engineered recombinant virus was capable of some level of viral replication in the 
swine host, although it is evident that rMN184ORF7-3’UTR (Group 4) and 
rMN184Δ618 (Group 6) were less successful at replicating inside the animal host as 
compared to the other groups, as measured by virus isolation on MARC-145 cells. We 
had detected antibodies to Group 6 virus (Fig. 2) with similar kinetics to all other 
treatment groups (except Group 4) that might be indicative of replication of this virus in 
the absence of overt CPE due to infection of MARC-145 cells. PRRSV vaccine strains 
MN184-P102 and Ingelvac
®
 PRRS MLV confirmed viral replication within the host, 
although replication of Ingelvac
®
 PRRS MLV from swine serum samples on cultured 
cells was more apparent than replication of MN184-P102 at all-time points. Viremia 
continued after virulent heterologous PRRSV challenge in all groups except the strict 
control.   
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In order to assess the ability of the immune response to reduce the replication of 
the JA-142 challenge virus after vaccination with each of the candidate viruses, we 
compared the levels of viremia for all treatment groups to that of the Challenge Control 
Group on Day 35, when presumably most virus remaining in the animals would be the 
challenge PRRSV strain. Groups 1-3 (chimeric viruses) and Groups 7-8 (traditionally 
prepared vaccines) had a statistically significant (p≤0.0001) lower percentage of viremia 
as compared to the Challenge Control (Group 9) at this time point (Fig. 3).  
3.4. Real Time RT-PCR 
PRRSV RNA was detected in all pigs of treatment Groups 1 – 8 prior to 
challenge except for Group 4 (rMLV/MN184ORF7-3’UTR), for which only 3 of the 10 
animals were positive for viral RNA by the day of challenge (Fig. 4). On Day 10, the 
various treatment viruses could be separated into two discrete categories. Those that had 
high levels of circulating viral RNA (>10
7
) include Groups 1-3 (chimeric viruses) and 
Group 7 (MN184-P102) while those that had less amounts of viral RNA (<10
6
) included 
Groups 4-6 and 8. Viral RNA detected in Group 6 animals suggested that this virus 
(rMN184Δ618) initially replicated at a lower rate, but eventually achieved RNA levels at 
Day 21 approximately equal to the viruses initially showing a higher level of circulating 
viral RNA. Group 4 animals revealed only 3 of 10 animals with circulating PRRSV 
RNA until after challenge, suggesting the virus does not replicate well in swine with a 
nucleocapsid gene and 3’UTR different from the rest of the pMLV genome. The 
remaining two viruses, inoculated into animal Groups 5 (rMLV/MN184-3’UTR) and 8 
(Ingelvac
®
 PRRS MLV), never reached above 10
7
 RNA copies/ml until after challenge. 
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On Day 28, after virus challenge with heterologous strain JA-142, PRRSV RNA 
was found in all animals, providing evidence of successful challenge conditions. No 
treatment groups were statistically different for viral load as compared to the Challenge 
Control, suggesting little or no effect on JA-142 replication in swine by prior 
vaccination, when analyzed by qRT-PCR (Fig. 4). These results are considerably 
different from those obtained with virus isolation (Fig. 3). 
3.5. Nucleotide Sequence Analysis 
RT-PCR followed by nucleic acid sequencing of the products was completed on 
pooled and extracted serum samples from day 21. Approximately 1000 bases of ORF1b, 
the entire structural protein region and most of the 3'UTR were examined to ensure the 
animals remained infected with the respective test virus. In all cases, no discrepancy 
between the consensus nucleotide sequences with the input viral genome was found 
(data not shown). Furthermore, all viruses showed very little nucleotide variation after 
21 days in 10 different animals. This indicated that all of the viruses, including the 
chimeras, were not undergoing demonstrable nucleotide change in the regions examined 
during the course of the experiment. 
3.6. Average Daily Weight Gain 
To assess the gross clinical effects of PRRSV vaccination and challenge on 
swine, all animals were weighed at each time point. From this data, average daily weight 
gain (ADWG) was derived for Days -3 to 21 (before challenge) and Days 21 – 35 (after 
challenge)(Fig. 5). Prior to virulent challenge, Group 10 (Strict Control) had a 
statistically significant (p≤0.01) higher ADWG than only rMN184ORF1/MLV (Group 
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1), signifying that only Group 1 vaccination significantly reduced animal growth during 
the period before challenge (identified as A in Fig. 5). After challenge, Groups 1 
(rMN184ORF1/MLV), 5 (rMLV/MN184-3’UTR), 6 (rMN184Δ618), and 9 (JA-142 
Challenge Control) showed significantly reduced ADWG (p≤0.01) compared to control 
animals. This reduced ADWG may be due to insufficient protection of animals by prior 
vaccination in Groups 1, 5 and 6. To monitor the ability of the various viruses to protect 
against reduced weight gain after JA-142 challenge, ADWG was compared to Group 9 
animals (Challenge Control)(identified as B in Fig. 5). In this comparison, 
rMLVORF1/MN184 (Group 2), rMLV/MN184ORF5-6 (Group 3), rMN184ORF7-
3’UTR (Group 4), MN184-P102 (Group 7), and Ingelvac® PRRS MLV (Group 8) 
showed a statistically significant (p≤0.05) higher ADWG than the JA-142 Challenge 
Control group.  
3.7. Clinical Observations 
Very few animals exhibited clinical signs after primary infection with the test 
viruses or with controls, with only one out of ten animals in each of Groups 5-7 showing 
mild discomfort (data not shown). This suggests that all treatments, although replicating 
variably in the host, did not mimic overt PRRS disease typically seen in the field. Only 
one animal in Group 6 experienced sustained mild lethargy and/or an intermittent cough 
after challenge (data not shown). In all, the mild clinical signs were to be expected and 
were a typical response to PRRSV infection in high health herds. The symptoms were 
not severe enough to have an effect on the outcome of the study, as attending 
veterinarians determined that no medication was necessary for resolution of clinical 
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signs for all animals enrolled in the study. 
3.8. Lung Pathology 
Upon completion of the study (Day 35), all animals were necropsied and 
assessed for lung pathology (Fig. 6). When compared to the Challenge Control (group 
9), five treatment groups exhibited a statistically significant reduction in gross lung 
lesions. Those groups were: rMN184ORF1/MLV (Group 1; P < 0.001), 
rMLVORF1/MN184 (Group 2; P < 0.01), rMLV/MN184ORF5-6 (Group 3; P < 0.001), 
the recently developed vaccine MN184-P102 (Group 7; P < 0.001) and, to a lesser 
degree, Ingelvac
®
 PRRS MLV (Group 8; P < 0.05). Three groups, rMN184ORF7-
3’UTR (Group 4), rMLV/MN184-3’UTR (Group 5), and rMN184Δ618 (Group 6), did 
not appear to have sufficient protection against the development of pulmonary lesions in 
the strain JA-142 respiratory challenge model as the average lung scores of these three 
groups were not significantly different (> 0.05) than the average score of the Challenge 
Control Group, which had over 50% of the lung displaying lesions. The Strict Control 
(group 10) had no lung lesions, thus indicating a valid challenge and successful bio-
containment.  
4. Discussion 
In this report, a respiratory challenge model was used to examine the vaccine 
efficacy of five chimeras and a deletion mutant engineered from PRRSV Type 2 strain 
viral clones that differed by 14.3% on a nucleotide basis. Two chimeras, 
rMN184ORF1/MLV (Group 1) and rMLVORF1/MN184 (Group 2) had been previously 
shown to successfully protect swine against challenge with heterologous PRRSV strain 
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SDSU73 [1]. The percent nucleotide identities between the Group 1 and 2 chimeras and 
SDSU73, over the available SDSU73 ORF2-7 sequence (EF442775), were 92.9% and 
89.7%, respectively. For this study, the nucleotide identities based on complete genome 
comparisons to strain JA-142 were 84.2% for Group 1, 90.2% for Group 2, 90.7% for 
Group 3, 90.9% for Group 4, 90.9% for Group 5, 80.4% for Group 6, 83.1% for Group 
7, and 91.0% for Group 8. One conclusion to draw from these comparisons is that 
percent similarity is not an accurate measure for determining which vaccine formula will 
provide the best protection from challenge, as has been shown previously [31]. Rather, 
PRRSV protection after vaccination seems to be directed towards specific gene regions 
that influence genome replication kinetics and/or viral interaction with the swine host. 
Since both ORF1 reciprocal chimeras protected against strain SDSU73 and now strain 
JA-142, and both replicated well in swine, we firmly established that genome 
components from both viral nonstructural and structural regions can influence the ability 
to protect against heterologous challenge [1]. The present work also suggests that simple 
exchange of just the ORF5-6 region of strain MN184 can protect against challenge with 
strain JA-142, possibly increased over the traditionally prepared Ingelvac
®
 PRRS MLV 
vaccine. This specific data reveals similar findings as those completed using a 
reproductive challenge model and infectious clones of two other PRRSV strains, 
attenuated vaccine Prime Pac PRRS

 and virulent NVSL #97-7895 [10]. The rMN184 
nsp2 deletion mutant (Group 6) also provided interesting results. As in previous study 
findings, where full-length rMN184 did not protect against challenge with strain 
SDSU73 [1], rMN184618 did not protect against challenge with strain JA-142. The 
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challenge viruses were different between those two studies, so additional parallel 
experiments must be completed to substantiate this preliminary finding. However, the 
data suggested that deletion of much of the nsp2 hypervariable region did not improve 
protection from heterologous PRRSV challenge. All of the data confirmed that PRRSV 
attenuation is complex, and may involve interactions between individual viral 
component and/or host factors.  
Novel findings concerning viral fitness in vivo were also presented. Virus 
isolation, which requires another round of MARC-145 cell infection and growth, 
revealed that rMLV/MN184ORF7-3’UTR and rMN184618 both replicated at a slower 
rate than most other viruses before challenge (Fig. 3). rMLV/MN184-3’UTR replicated 
quite well in vitro. However, when samples were directly assessed for the level of serum 
vRNA by qRT-PCR, rMLV/MN184-3’UTR along with rMLV/MN184ORF7-3’UTR 
may have replicated very poorly in swine, suggesting a PRRSV strain does not easily 
tolerate a nucleocapsid gene or protein and/or a 3’UTR different from the rest of the 
genome. rMN184618 showed evidence of adequate replication in vivo when monitored 
by qRT-PCR, different from what was detected by the virus isolation technique. The 
implications of this finding are that viral fitness must be directly examined in the host, 
that replication of chimeric viruses in the host animal are not predictable and, therefore, 
one must assess several parameters when evaluating viruses for biological use. We have 
also shown that some chimeric viruses can be readily utilized as vaccines, although 
traditionally prepared vaccines can perform as well or better against specific virulent 
strains.  
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Table 1. Primers Used in Preparation of Recombinant PRRSV Infectious Clones. 
Forward Primers Indicated by a Slash (/) Following the Name and Reverse Primers 
by a Slash Before the Name. Primers Were Positioned Based on Genomic 
Sequences pMLV (MLV; EF484033) or pMN184 (MN184; EF484031) (Most 
Primers Anneal to Both Sequences). 
 
Primer Nucleotide Position Sequence 
Synthesis of PRRSV recombinants 
MLV-
ORF6-F/ 
MLV 14192-14217 5′-GCTACGCGTGTACCAGATATACCAAC 
/MLV-
ORF7-R 
MLV 15249-15277 5′-
CAAGAATGCCAGCTCATCATGCTGAGGGT 
184-3′UTR-
F/ 
MN184 14856-14884 5′-
ACCCTCAGCATGATGAGCTGGCATTCTTG 
/184-3′UTR-
R 
MN184 15011-15099 5′-GTCTTTAATTAACTAG(T)30AATTTCGGC 
184-3122-F/ MN184 2494-
2503/3122-3136 
5′-AAGCTCGAGCTGTGGGTTTGTGATG 
/184-4083-R MN184 4065-4091 5′-AAAACCGGTCGCACAGGTCGACAAGTG 
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Table 2. Nucleotide and Amino Acid Changes to Recombinant Viral Parent Due to 
Clone Construction. 
 
  
Construct Region NT Changes AA Changes 
pMLV/MN184ORF5-6 GP4 11 0 
GP5 81 31 
M 37 6 
pMLV/rMN184ORF7-
3’UTR 
M 5 2 
N 26 6 
3’UTR 9 - 
pMLV/MN1843’UTR 3’UTR 9 - 
pMN184618 nsp2 618 206 
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Table 3: Treatment List 
Group # 
 
Treatment 
 
Treatment Titer 
(log 10 TCID50 / ml) 
Challenge 
 
1 rMN184ORF1/MLV 5.02 JA-142 
2 rMLVORF1/MN184 5.70 JA-142 
3 rMLV/MN184ORF5-6 5.63 JA-142 
4 rMLV/MN184ORF7-3’UTR 5.50 JA-142 
5 rMN184Δ618 5.35 JA-142 
6 rMLV/MN184-3’UTR 4.96 JA-142 
7 MN184-P102 4.49 JA-142 
8 Ingelvac
®
 PRRS MLV 4.09 JA-142 
9 N/A N/A JA-142 
10 N/A N/A N/A 
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Figure 1.  Genome schematic of PRRSV, the Two Infectious Clones Initially 
Derived (pMLV and pMN184 [1]), Chimeras, and Deletion Mutant Prepared for 
the Present Study. 
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6 
Figure 2. Mean PRRS ELISA 2XR S/P ratios. 
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Figure 3.  Viral Load, Determined by Virus Isolation on MARC-145 cells, in Swine 
Serum at All Time Points After Intramuscular Inoculation with 4.79 logs of Virus.   
 
 
1 
The challenge control and strict control groups received only dilution medium. On Day 
21, all animals except the strict control group were intranasally challenged with 3.8 logs 
of strain JA-142.  Results for each animal of each group were collated and the percent 
positive per group was then determined.  
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Figure 4.  Viral Load as Determined by qRT-PCR and Plotted as Viral RNA Copies/ml Serum. 
8
8
 
89 
 
Figure 5.  Growth Effects of Chimeric and Parental Viruses on Swine.  
 
1 
All experimental pigs were weighed at Days -3, 21 and end of study. The average daily gain 
weight (ADG) from 10 pigs in each group was calculated at period of -3-21 and 21-35 dpi. The 
mean was plotted and the standard error of the mean (SEM) represented as error bars. 
Statistically significant (≤0.01) lower average daily weight gain than the Strict Control group for 
the relevant time period was specified by the letter A. Statistically significant (≤0.01) higher 
average daily weight gain than Challenge Control group for Days 21-35 is represented by the 
letter B. 
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Figure 6.  Average Lung Scores Recorded at 35 Days Post Vaccination and 14 Days Post 
Challenge. 
 
 
1 
The results were plotted as mean values of gross lung lesions from 10 pigs in each group, and 
SEM values from different pigs designated by error bars. An asterisk indicates the average lung 
score of the group is lower than the challenge control group (* p < 0.05).  
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CHAPTER 4.  DEVELOPMENT OF ATTENUATED PORCINE REPRODUCTIVE AND 
RESPIRATORY SYNDROME VIRUS ISOLATES THROUGH CONTINUOUS CELL 
PASSAGE BY MULTIPLE WELL LIMITING DILUTIONS 
 
Joshua S. Ellingson, Eric Vaughn, Sarah Layton, and Michael B. Roof
 
 
Abstract  
In an effort to explore alternative options to develop modified live PRRSV vaccine 
candidates, an innovative cell passage processed was utilized.  Virulent field isolates, MN184 
and MR007, were used as parent viruses to establish in vitro growth of twelve individual cohort 
isolates for each strain.  Isolates were each initially established on one 96 well plate.  Thereafter, 
each column was separately passed concurrently by limiting dilution, allowing for natural 
mutants to develop twelve potentially unique progeny isolates from each parental strain.   
Isolates were passed until significant genomic changes were detected.  Nsp2 deletions were 
targeted, as recent evidence has indicated nsp2 deletions may be involved with isolate 
attenuation.  At passage 50 isolates were tested for safety in both a respiratory growing pig safety 
study and a gilt reproductive safety study.  Numerous parameters of safety were collected from 
both studies and revealed significant attenuation of the isolates.  These studies suggest the cell 
passage process by limiting dilution is a viable and efficient tool for the development of multiple 
clones for vaccine candidate assessment. 
1. Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSV) is an enveloped single-
stranded positive-sense RNA virus classified under the family Arteriviridae, and genus 
Arterivirus [1].  The virus causes a disease known as Porcine Reproductive and Respiratory 
Syndrome (PRRS) which is classically seen as reproductive failure in breeding females and 
respiratory disease in growing swine.  The reproductive failure is associated with mid to late 
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term abortions, increased numbers of mummified fetuses and weak born piglets, and fewer 
healthy born piglets [2].  With the aforementioned clinical signs, PRRS can have a significant 
negative impact on the productivity of a herd.  It has been estimated that PRRS costs the United 
States pork producing industry around 664 million dollars a year [3].  Compounding the situation 
is the fact that PRRSV is endemic in most swine producing countries and has a similar economic 
effect elsewhere.  To avoid these economic hardships, it is important for producers to have PRRS 
prevention and elimination/management programs in place. 
Current control strategies to prevent the spread of the virus within and between herds 
includes: the proper management of breeding animals, removal of infected individuals, strict 
biosecurity measures, serum inoculation, and the use of vaccines.  Both inactivated and modified 
live vaccines are commercially available.  Inactivated vaccines provide a high level of safety but 
are generally considered as ineffective or as conveying a very limited degree of efficacy.  
Attenuated live vaccines have been widely used to reduce the transmission and clinical disease 
caused by virulent wild-type (wt) viruses.  Although modified live vaccine efficacy varies against 
heterologous isolates, they remain the best vaccination option available to combat the disease.  
The development of a new generation of vaccines capable of providing improved and consistent 
protection against heterologous isolates with the ability to detect wt infection in vaccinated 
animals would be a tremendous asset to the swine industry and is the focus of this research.    
The PRRS genome is approximately 15,400 kilobases in length and is organized into at 
least 10 open reading frames, numbered (1a, 1b, 2, 2b, 5a and 3-7) [4, 5].  Nonstructural proteins 
(nsps) are encoded by ORF1a and 1b, which occupy three fourths of the entire genome.  Due to 
the essential nature of the structural proteins for production of viable virus, the nsps are an area 
of focus for the generation of deletion marker vaccine candidates [6].    
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The nsp2 protein is the largest PRRSV protein and contains the most variable region in 
the genome [7-9].  The nsp2 gene is also highly antigenic, containing numerous B-cell epitopes 
[10].  Investigation of potential functions of nsp2 revealed that portions are critical for viral 
replication while others were unnecessary [11].  The genetic flexibility of nsp2 allows for foreign 
genes to be inserted successfully into the nonessential region to serve as a marker allowing for 
users to successfully differentiate infected and vaccinated animals (DIVA) [6, 12].  Interestingly, 
many field viruses have been identified with variously sized deletions in the nsp2 gene [8, 13-
20].  However, recent reports indicate the size and location of deletions within nsp2 are not 
linked to increases in virulence or pathogenicity [21-24].  
Moreover, recent work has reported nsp2 deletion mutants to be attenuated in vivo with 
good stability [24-27].  Isolates with nsp2 deletions have been reported to be directly linked to 
attenuation while other studies have implicated nsp2 as a potential cause [6, 28].  The cause of 
attenuation may be due to the loss of nsp2’s antagonistic effects on the production of interferon 
beta (IFN-β), an important part of the innate immune response against early viral replication [29, 
30].  Nsp2 has also been found to counteract the antiviral function of interferon-stimulated gene 
15 which functions in the regulation of antiviral immune responses [31].  Attenuation may also 
be linked to viral replication, as nsp2 deletions have been reported to increase viral growth 
kinetics in vitro while limiting replication in vivo [24].  It was determined that nsp2 deletions 
may be one method in which isolates naturally attenuate themselves when being passed 
continuously in vitro and therefore could provide guidelines to direct isolate testing as potential 
vaccine candidates.  In addition, deletion mutants could provide additional utility in the 
development of DIVA technologies if a successful vaccine candidate could be developed.   
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In an attempt to create new deletion mutants through continuous in vitro passage, two 
recently isolated circulating virulent field isolates (MN184 (MN/01/A2) and MR007) were 
utilized.  Each isolate was used to develop twelve theoretically distinct clones within one culture 
plate using a unique cell passage process.  After the first passage, progeny isolates were kept 
separate from each other and were passed weekly by limiting dilution.  This process is believed 
to be a more efficient method to obtain and develop multiple independent clones during passage 
as compared to traditional methods.  Isolates with deletions within nsp2 were specifically 
targeted for evaluation as a fact finding mission to determine if a correlation with attenuation 
could be identified as reported by others.  In vitro adapted progeny isolates were selected and 
evaluated for attenuation in an initial 14 day growing pig respiratory trial and a pregnant gilt 
reproductive model.   
2. Materials and Methods 
2.1 Cell Passage 
To facilitate viral growth in vitro, 96 well cell culture plates were planted with MA-104 
cells (ATCC CRL2621) and incubated with minimum essential medium (EMEM, SAFC 
Biosciences M56416) with 10% fetal bovine serum (Invitrogen) and 5% CO2 at 37°C.  Once 
cells had incubated for 3 days, 100 µL of parent virus, either MN184 (MN/01/A2) or MR007, 
were added to each well of an entire row on the culture plate.  Each well was then used to make 
four 1/10 dilutions down each respective column.  After dilution, 100 µL of fresh media was 
added over the top of each well.  Plates were incubated for 3-8 days prior to being checked for 
cytopathic effect.  After reading the plates, the highest positive dilution of each column was 
passed onto the same column of another plate with 3 day old MA-104 cells.   
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On the new plate four 1/10 dilutions were performed, media was overlaid, and plates 
were again incubated.  This process was performed continuously through in vitro cell passage 50.  
Occasionally, if a column would display no growth the lowest dilution was passed in an attempt 
to harbor enough infectious virus to maintain the passing infection.  Subsequently, if there were 
still no signs of CPE on the next plate another column was used to plant the next plate.  Progeny 
isolates were strictly kept separate, with the exception of total loss of virus, to encourage the 
concurrent development of twelve unique isolates.  Total loss of virus occurred twice through 
passage 50.  At every 10 passages positive samples were frozen at -70ºC as a backup.  If a virus 
was totally lost the last positive sample was thawed and used for recovery. 
2.2 Viral Isolates 
MR007, is an isolated virulent field virus from a 2007 PRRS outbreak that exhibits an 
ORF5 1-7-4 RFLP pattern and has a JA-142 like nsp2 region.  MN184 (MN/01/A2) is a very 
pathogenic isolate that appeared in North America in 2002 causing high mortality and severe 
reproductive disorders.  This isolate has a 131 amino acid deletion in the nsp2 region as 
compared to VR-2332, the type 2 prototype strain.  Furthermore, MN184 has been found to have 
the shortest PRRS genome found to date at 15,019 kb [11, 15].  Deletion mutants created through 
the passage process were referred to as 96 well deletion mutants while MR007 #9 contained no 
significant deletions in the nsp2 region but was selected to be used as a comparison to the 
selected MR007 nsp2 deletion isolate. 
2.3 Nucleotide Sequence Analysis 
Nucleotide sequence analysis was performed from both in vitro cell cultures and from 
study animal serum samples.  For the in vitro samples, QIAamp Viral RNA Mini kit (Qiagen Inc, 
Valencia, CA) was used for the ribonucleic acid (RNA) extractions while the Total Nucleic Acid 
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MagNA Pure kit (Roche Applied Science) was used to extract from the collected swine serum.  
SuperScript® III First-Strand Synthesis (Invitrogen Corp, Carlsbad, CA) was used to create 
complementary deoxyribonucleic acid (cDNA) per the manufacturer’s recommendations.  The 
cDNA product then underwent polymerase chain reaction (PCR) in a GeneAmp® PCR System 
9700 (Applied Biosystems) 96 well machine with the following configuration: an initializing 
step for 5 minutes (min.) at 95°C, 35 cycles of a denaturation step at 95°C for 30 seconds (sec.) 
an annealing step at 53°C for 30 sec. followed by an extension step at 72°C for 150 sec., and 
finally a single elongation step at 72°C for 5 min.  Samples were held at 4°C until removal from 
the thermocycler.  Each PCR well was set up accordingly: 25µL of 2X AmpliTaq Gold 
Mastermix (Applied Biosystems), 21µL DEPC Water (EMD Chemicals, Gibbstown, NJ), 2 µL 
of cDNA template, and 1µL of each respective primer [Table 1].   
The PCR products were then purified with the Wizard® DNA Clean-Up System 
(Promega, Madison WI) per the manufacturer’s recommendations.  Samples were then placed 
into a Savant Speedvac DNA 110 (Global Medical Instrumentation, Ramsey, MN) at medium 
speed for 10 min. to remove any residual isopropanol.  Samples were then mixed with 10 µL of 
loading dye and loaded onto a 1.5% agarose gel.  Electrophoresis was performed by applying 
120 volts for 45 min.  Bands of the appropriate size were visualized and underwent purification 
with the Wizard® SV Gel and PCR Clean-Up System (Promega). 
Samples were then sent to Iowa State University (ISU) DNA Facility for sequence 
analysis where the sequencing reactions were set up with the appropriate primers [Table 1].  At 
ISU an Applied Biosystems 3730xl DNA Analyzer was used.  Sequences were analyzed with 
GeneTool Version 2.0 (BioTools Inc.).  The ORF5 sequences were classified according to their 
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restriction fragment length polymorphism cut pattern as outlined by the University of Minnesota 
Veterinary Diagnostic Laboratory.  
2.4 Respiratory Safety Trial 
For this study, twenty-five 3 week old commercial crossbred pigs naïve to PRRSV were 
randomly split by weight into groups of 5 for a 14 day respiratory safety trial.  All animals were 
housed at a research facility and blinded to all individuals working with the animals throughout 
the study.  Animals received 5.0 logs of virus in a 2 ml intramuscular injection in the neck 
containing either MN184 pass 51 clone #6, MR007 pass 51 clone #2, MR007 pass 51 clone #9, 
wt MR007, or phosphate buffer solution (PBS) for the negative controls.  The three isolates were 
selected out of the 12 developing clones from each parental virus on the basis of containing nsp2 
deletions (MN184 #6 and MR007 #2) or based on replication kinetics in vitro (MR007 #9 
consistently replicated to lower levels as compared to cohorts).  Animal facility constraints 
limited the study to just 5 groups.  All viruses were diluted with minimum essential medium 
(MEM; Sigma, St. Louis, MO.) containing 2% fetal bovine serum (FBS; Sigma, St. Louis, MO.) 
in order to deliver 5.0 logs of virus to each animal.  Viral titers were determined by TCID50/ml 
[32, 33].   
The study concluded at day 14 upon which all animals underwent humane euthanasia and 
necropsy by a licensed veterinarian.  Assessment of isolate virulence was evaluated by quantity 
of gross lung lesions and average daily weight gain.  Blood samples were collected prior to 
inoculation on study day 0 and on days 7 and 14 to evaluate ability of isolates to induce PRRS 
specific antibodies. 
The lungs of all animals in the pig safety study were evaluated at necropsy for percent 
consolidation consistent with PRRSV infection. Lungs were scored for each individual lobe and 
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total gross lung pathology using a standardized scoring system [34]. The final observation score 
equaled the weighted sum of all the individual lobe scores.   
2.5 Reproductive Safety Trial  
With satisfactory results from the respiratory trial, the same isolates were tested again in 
a gestating gilt reproductive model to further ascertain the safety of the isolates.   
The reproductive safety trial included sixteen PRRS ELISA negative commercial crossbred gilts 
at 90 ± 4 days of gestation housed in a research facility and blinded to all animal caretakers and 
investigators.  Animals were randomly divided into four treatment groups consisting of the same 
cell passaged articles from the respiratory trial and one negative control group.  Females were 
inoculated intranasally with 2.0 mL per nostril with either inoculum or PBS for the negative 
control group.  All viruses were prepared as described for the respiratory trial, with the exception 
of the gilts received 5.0 logs of virus in 4.0 ml.  The study ended for each gilt and her piglets 21 
days after their respective day of farrowing (DOF).   
Abortions and farrowing data were recorded for each female.  The day of farrowing was 
defined as the day the first live born pig of the litter was delivered.  Gilts were observed 
periodically from at least 6:00 AM to 10:00 PM daily.  Litter observations included the number 
of abortions, stillbirths, mummies, live piglets, and weak born live piglets for each female.  
Piglets found dead due to being crushed by the dam were recorded and confirmed with a 
necropsy.   
All gilts had blood drawn at day 0, 7, 14, 21, day of farrowing (DOF), 7 days after 
farrowing (DOF+7), 14 days after farrowing (DOF+14), and 21 days after farrowing (DOF+21).  
In addition, live piglets had blood collected on DOF, DOF+7, DOF+14, and DOF+21 while dead 
piglets had blood or thoracic fluid collected immediately upon examination regardless of study 
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day.  Blood was collected for evaluation of viremia and development of PRRSV specific 
antibodies.  Additional data was collected to serve as further evidence of safety including: 
clinical signs of animals, gilt rectal temperatures, piglet average daily weight gain, and 
reproductive performance. 
2.6 Serology 
Whole blood was collected from each animal via venipuncture.  Samples were returned to 
the laboratory for separation from the clot by centrifugation.  Serum was then decanted into 
screw-cap cryogenic vials and stored for a maximum of 24 hours at 4°C or at -70°C until testing 
could be performed.  Serum samples were analyzed for PRRSV specific antibody using the 
IDEXX HerdChek® PRRS ELISA 2XR (IDEXX Laboratories Inc, Westbrook, ME). All tests 
were performed as described by the manufacturer’s instructions.  Samples were considered 
positive for PRRSV antibodies if the sample-to-positive (S/P) ratio was at least 0.4.   
2.7 Average Daily Weight Gain 
As another parameter to gauge the health status of study animals, average daily weight 
gain (ADWG) was recorded.  Animal weights were recorded on a scale that was calibrated prior 
to each use.  For the respiratory safety study, animals were weighed 3 days prior to vaccination 
(Day -3) and at necropsy (Day 14).  For the reproductive safety study, all piglets delivered were 
weighed within 8 hours of farrowing and all remaining live piglets were again weighed 21 days 
later for analysis. 
2.8 Reproductive Safety Trial Viremia 
Both gilt and piglet serum were tested via reverse transcriptase polymerase chain reaction 
(RT-PCR) for the presence of PRRSV nucleic acid.  Serum was extracted by the Roche MagNA 
pure extraction robot with the Total Nucleic Acid MagNA Pure kit (Roche Applied Science).  
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The RT-PCR was performed with the AgPath-ID™ NA and EU PRRSV Multiplex (Applied 
Biosystems) per the manufacturer’s instructions.  The reactions were run on a Roche Lightcycler 
480 96 well machine with the following configuration: an annealing step at 45°C for 10 min., 
denaturation at 95°C for 10 min., and 40 cycles of denaturation at 97°C for 2 sec. followed by an 
annealing step at 60°C for 40 sec., and finally a cooling step at 40°C for 40 seconds. 
2.9 Reproductive Safety Study Animal Clinical Observations 
All study animals were observed daily for overall health and clinical signs associated 
with PRRS.  Each animal was evaluated for respiration, behavior, and cough with scores 
assigned for each category.  Possible scores ranged from 0 (normal) to 1 (abnormal).  Abnormal 
behaviors were defined as abnormal respiration, abnormal behavior such as lethargy, and the 
presence of a cough.  A total daily score was recorded based on the sum of the 3 individual 
scores.  Any dead piglets were assigned a score of 3 and then were weighed and subsequently 
had a necropsy performed to determine the likely cause of death.  In addition to the daily 
observations, gilt rectal temperatures were taken periodically beginning with the day prior to 
inoculation (day -1) through study termination (DOF+21).   
2.10 Statistics/biometrics 
All data for the respiratory safety and reproductive safety studies were imported into SAS 
version 9.1 for management and analysis.  All parameters were compared between groups 
(pairwise) 1 – 4 vs. 5 for both the pig and reproductive studies and groups 1 – 3 vs. 4 for the 
respiratory study.  In compliance with the methods recommended by APHIS, only two-sided 
results were reported and all comparisons were at α=0.05.  The specific methods used to analyze 
data are shown in table 2. 
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3. Results 
3.1 Sequence Analysis 
The viruses undergoing continuous cell passage had genomic sequence analysis 
performed at approximately every 10 passages on the nsp2 region and on the ORF5 region at 
passage 50.  Genomic changes outside of nsp2 and ORF5 were not monitored.  As expected, 
several isolates had developed natural deletions in the nsp2 region throughout the process.  At 
cell passage 50 MN184 #6 had a continuous 6 nucleotide deletion in the nsp2 region, expected to 
result in the loss of 2 amino acids.  MR007 #2 at cell passage 50 exhibited a continuous 63 
nucleotide deletion in the nsp2 region which resulted in the loss of a continuous 21 amino acid 
sequence.  MR007 #9 at pass 50 remained similar to the parent strain and was selected for testing 
for comparison to other isolates.   
Samples from the reproductive safety trial also underwent sequence analysis to determine 
how stabile the viruses were in vivo. All PCR positive piglet blood samples from the final day of 
the study (DOF +21), underwent attempted sequence analysis for nsp2 and ORF5.  At least one 
sequence was successfully attained from each vaccinate group.  All isolates from the gilt safety 
trial remained stable in the evaluated regions after in vivo replication.  The nsp2 region 
sequencing from each individual animal revealed only a few substitutions for each virus.  
Substitutions resulting in amino acid changes are summarized in table 3 and are described in 
comparison to MN184A and JA142 AY424271.  The ORF5 regions were also sequenced and 
revealed only a few insignificant changes (data not shown). 
3.2 Respiratory Safety Trial Lung Pathology 
Upon completion of the study on day 14, all animals were assessed for lung pathology 
[Figure 1].  Using ANOVA to compare group mean lung scores, only the wt MR007 group had a 
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significant increase in clinical lung scores as compared to the negative control group.  The 
MR007 #9 group had significant reductions in lung scores as compared to the wt MR007 group.  
The lung scores indicate that the cell passage process significantly reduced the virulence of the 
MN184 #6 and MR007 #9 isolates while the MR007 #2 isolate containing the nsp2 deletion may 
still be capable of causing some degree of respiratory disease.   
3.3 Average Daily Weight Gain 
For the respiratory safety study, average daily weight gain analysis revealed no 
statistically significant differences for either group mean initial body weight or average daily 
gain amongst all treatment groups.  The wt MR007 group had a slightly higher mean initial body 
weight than the other groups which may account for the lack of statistical differences in ADWG 
as compared to the other groups.  For the reproductive safety study, piglets in the MR007 #2 
group had significantly lower mean body weight at farrowing than the negative control group.  
Piglets in all treatment groups had significant reductions in ADWG as compared to the negative 
control group.   
3.4 HerdChek ELISA 
For the respiratory safety study, on day 0 and 7 all animals were negative via the IDEXX 
HerdChek® PRRS ELISA 2XR.  On day 14 all animals in the MN184 Pass 51 #6 group and 
most animals in group 4 (wt MR007) had seroconverted while the MR007 pass 50 treatment 
groups displayed poor seroconversion [Figure 2].  The wt MR007 treatment group was only 
statistically different from the poor seroconverting MR007 #2 group.  
For the reproductive safety study, all animals were again negative on days 0 and 7.  
However, by day 21 nearly all gilts that received virus as a treatment were positive, indicating 
the pigs in the respiratory trial may have needed additional time to develop detectable levels of 
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antibody.  Gilts in the MN184 treatment group all remained positive by ELISA for the duration 
of the study.  Piglets were found to have a considerable amount of PRRSV specific antibody.  
The MR007 #9 and MN184 #6 groups displayed significant increases in positive tests as 
compared to the piglets belonging to the negative control group for all sample collection dates.  
The MR007 #2 treatment group piglets were found to only be statistically distinct from the 
negative control group at DOF+7.  ELISA findings for both studies provided evidence that all 
isolates are capable of inducing a PRRSV specific antibody response.  Interestingly, the onset of 
antibody detected in the MN184 treatment group was earlier than the MR007 pass 51 treatment 
groups.   
3.5 Gilt Reproductive Performance 
Females farrowed relatively normal and healthy litters as outlined in (Table 4), with the 
exception of 1 gilt in the MR007 #2 group who produced only 3 stillborn piglets.  Due to facility 
and labor limitations, only 4 gilts were used for each isolate.  With such a small sample size it is 
difficult to make concrete conclusions over this data.  However, there were no dramatic signs of 
virulence in any of the tested isolates.  No statistical differences were found for any of the 
reproductive performance variables measured when compared to the control group.  These 
findings suggest that the described attenuation process has been successful in reducing the 
amount of reproductive failure caused by each isolate.     
3.6 Mortality of Piglets, Pigs, and Gilts 
For the respiratory safety study no animals were lost during the study.  However, for the 
reproductive safety study 6 piglets were lost from the DOF to DOF+21.  These losses still fall 
within the expected range of piglet mortality prior to weaning.  One gilt in the MR007 #2 
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treatment group was euthanized due to illness resulting from a retained placenta.  The gilt 
delivered just 3 stillborn piglets so no piglet performance data was compromised. 
3.7 Viremia 
Gilt viremia as detected by RT-PCR was relatively short for most groups [Figure 3].  All 
treatment groups had a significant increase in animals positive for PRRS RNA at day 14 while 
the MN184 #6 group was also statistically distinct at day 7.  The negative control group had 1 
animal test positive at DOF+7, which was included in the statistical analysis.  This was likely the 
result of sample contamination sometime along processing as this was the only positive test out 
of this group. 
For the MR007 treatment groups, the majority of the piglets were negative on the day of 
farrowing.  However, by DOF+21 most piglets belonging to the MR007 #9 and MN184 #6 
treatment groups were positive, presumably due to horizontal transmission of virus.  All 
treatment groups exhibited a significant increase in the number of piglets testing positive for 
PRRS RNA, with the exception of MR007 #2 at DOF+7 which lost significance due to 4 out of 
the 26 piglets in the negative control group testing positive on that day.  The cause of positive 
samples from the negative control group on this study day are unknown, but were likely the 
results of contamination somewhere along the line of sample collection, handling, or processing 
as no other negative control group samples were PCR positive prior to or after this occurrence 
[Figure 4].  While all isolates were capable of replicating in vivo, the MR007 passaged viruses 
were less efficient.  
3.8 Reproductive Safety Study Clinical Observations 
Clinical observations were recorded for the reproductive safety study as supporting data 
for remaining isolate virulence.  With the exception of the euthanized gilt, only a few isolated 
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events of abnormal scores of 1 were documented.  No groups were statistically different from the 
negative control group throughout the study.  Mean gilt group rectal temperatures were also 
collected and compared to the negative control group.  Higher mean rectal temperatures were 
noted at day 7 (MR007 #9 and MR007 #2) and day 14 (MN184 #6).  Body temperatures for gilts 
in all treatment groups remained normal throughout the remainder of the study.  For the piglet 
clinical observation scores, increases in piglet clinical abnormalities in the MR007 #9 and 
MR007 #2 treatment groups were noted.  All other clinically abnormal animals were not severely 
affected and no abnormalities compromised the outcome of the study. 
4. Discussion 
The aim of this study was to develop attenuated PRRSV isolates from virulent field 
strains by continuous in vitro passage for potential use as future modified live vaccines.  The 
ability to use naturally occurring nsp2 deletions as a determinant of isolate attenuation from in 
vitro passage was also a side component of this project.  Typically, when viruses replicate in cell 
lines derived from a different species the viruses tend to naturally attenuate during the process of 
adapting to the cell line used.  Early mutations are frequently related to adaptation while later 
stage mutations are more likely to be related to isolate attenuation [28, 35].  Currently available 
modified live PRRS vaccines were developed by passing pathogenic isolates continuously in cell 
culture to reduce virulence.  Potential vaccine isolates are then tested for safety, efficacy, and 
stability with in vivo models.  This process is laborious, costly, and time consuming.  The 
development of methodologies to improve the efficiency of this process is needed.   
In this report, a passage process is described in which single isolates were passed 
multiple times by multiple well limiting dilutions to increase the efficiency of developing 
naturally attenuated clones.  Frequent sequence analysis was used to screen progeny viruses for 
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genomic changes and to guide selection of isolates for potential level of in vivo attenuation.  In 
the respiratory trial, all cell passage isolates had no statistical differences for lung pathology or 
average daily weight gain as compared to the negative controls.  The MR007 #9 group had 
statistically significant reduced lung scores as compared to the parent group (wt MR007).   A wt-
MN184 was not used in this study in an attempt to reduce the number of animals necessary for 
this phase of investigation, but has been tested previously [32].  Johnson et al. inoculated ten 2-3 
week old pigs with MN184 at cell culture passage 1 and documented the death of 2 pigs in that 
group by the first 14 days of the study.  Lung pathology scores were not collected for the MN184 
group, but the group mortality rate speaks for the general virulence of the parental wt isolate.  In 
the pig respiratory trial, no animals were lost for any treatment group over the course of the 
study.   
Results for the reproductive safety trial mimicked those from the respiratory trial.  When 
compared to the negative control group, all reproductive performance parameters and gilt clinical 
observations had no statistical differences for any of the tested isolates.  ELISA results for both 
trials indicated all isolates are capable of inducing the production of PRRSV specific antibodies 
by day 21 in the gilts.  Viremia detected by RT-PCR showed that the virus attained detectable 
levels within the blood for only short periods of time in the gilts.  Transplacental transmission of 
virus with subsequent lateral transmission to littermates in all groups was documented.  While 
congenital transmission of virus did occur, it didn’t negatively affect the performance of all 
groups.  The MN184 #6 group had no statistical differences in piglet clinical observations when 
compared to the negative control group which is a phenomenon that has been previously 
described with currently available attenuated vaccines [36].  All passaged isolates were capable 
of replication and inducing seroconversion in vivo and were less virulent than the parent viruses.  
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However, the isolates displayed some residual ability to cause disease and potential production 
losses, so they will continue to be passaged in cell culture in an attempt to further attenuate the 
viruses.     
This work also provides evidence that nsp2 deletions may be a component of the 
attenuation of in vitro passaged isolates.   Naturally occurring nsp2 deletions were purposely 
selected to be screened for virulence to determine if nsp2 deletions could be used to gauge levels 
of in vitro attenuation.  Both nsp2 deletion mutants tested (MN184 #6 and MR007 #2) were 
attenuated in vivo.  Results from the two safety studies revealed, the MR007 passaged isolate 
with the 63 nucleotide deletion (MR007 #2) was less attenuated than the cohort isolate without a 
noted nsp2 deletion (MR007 #9) at the same cell passage (passage 50).  For the respiratory trial 
only the MR007 #9 group was statistically different from the wt parent virus for lung pathology.  
However, both isolates were statistically indistinguishable from the negative control group 
indicating both were attenuated to some degree.  The decreased ability of the nsp2 deletion 
mutants to replicate in vivo has been reported previously, and could be the cause of the reduced 
levels of viremia and slower development of antibody reported here with MR007 #2 [25, 37].  
Without additional data, it is unclear if the nsp2 deletions were directly involved with isolate 
attenuation or were a coincidental change.     
Nsp2 deletions mutants are considered to be viable potential vaccine candidates worthy 
of developing and testing.  However, further research is needed to clarify their role in isolate 
attenuation.  The ability to identify attenuated isolates with molecular techniques would greatly 
reduce the cost of developing new vaccines and significantly speed up the process.  If nsp2 
deletions are not involved with isolate attenuation, they still hold potential for the future 
development of successful DIVA technologies.   
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Without a better understanding of viral components important for virulence and host 
immunity, the industry will continue to rely on trial and error approaches for the development of 
new and improved vaccines.  Until then, the passage of virulent isolates in cell culture by 
limiting dilution is an efficient and viable technique to concurrently develop multiple potential 
vaccine candidate isolates.   
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Table 1. Primers Used in Preparation and Sequencing of PRRSV Isolates. 
 
Primer Target Sequence 
PCR Amplification of cDNA 
NamNsp2U Nsp2 CTGCGGCCTTRGACAGGAACGG 
NamNsp2L Nsp2 TGTCHACCCKATCCCACATGCG 
PRRS-Out1 ORF5 GTACGGCGATAGGGACACC 
PRRS-Out2 ORF5 CCAGAATGTACTTGCGGCC 
Sequence Analysis 
NamNsp2U MN#6 Nsp2 CTGCGGCCTTRGACAGGAACGG 
NamNsp2L MN#6 Nsp2 TGTCHACCCKATCCCACATGCG 
NspMR-U1 MN#6 Nsp2 CTGATCAGGTGTGCTTGGGG 
NspMR-L1 MN#6 Nsp2 CCCCAAGCACACCTGATCAG 
Nsp-MR-U2 MN#6 Nsp2 GCACCGCCACCTTCTCCAC 
Nsp-MR-L2 MN#6 Nsp2 GTGGAGAAGGTGGCGGTGC 
NamNsp2U MR#2/9 Nsp2 CTGCGGCCTTRGACAGGAACGG 
NamNsp2L MR#2/9 Nsp2 TGTCHACCCKATCCCACATGCG 
MN445U MR#2/9 Nsp2 AAGTCTTGAAGAATGCTTGGC 
MN445L MR#2/9 Nsp2 GCCAAGCATTCTTCAAGACTT 
MN41020U MR#2/9 Nsp2 GCATTGCCGCTGAGTGRGGAT 
MN41020L MR#2/9 Nsp2 ATCCYCACTCAGCGGCAATGC 
PRRS-Out1 ORF5 GTACGGCGATAGGGACACC 
PRRS-Out2 ORF5 CCAGAATGTACTTGCGGCC 
Letter Key:   
A – Adesosine T - Thymidine K - G or T 
G – Guanosine R - A or G Y - C or T 
C – Cytidine H - A, C or T  
 
 
 
 
 
113 
 
Table2. Summary of Statistical Methods of Analysis for Collected Parameters. 
 
Safety 
Study 
Parameter Specific Evaluation To 
Be Conducted 
Statistical Method  
of Analysis 
Respiratory Mean Lung  
Scores 
Mean lung scores for 
each group 
ANOVA 
Respiratory 
and 
Reproductive 
 
 
Serology  Number of animals in 
each group serologically 
positive/total number of 
animals in each group 
Fisher’s Exact Test 
Respiratory 
and 
Reproductive 
Weights and 
ADWG 
Mean Data ANOVA 
Reproductive Gilt 
Reproductive 
Performance 
1. Total Piglets Kurskal-Wallis / 
Wilcoxon Two 
Sample Test 
2. Stillborn 
3. Healthy Live Piglets 
4. Weak Live Piglets 
5. Mummies 
6. Live Pigs at DOF 21 
Reproductive Gilt and 
Piglet 
Clinical 
Observations 
 Gilts/Piglets with score 
> 0 for at least one day 
Fisher’s Exact Test 
Reproductive Gilt Rectal 
Temperatures 
Mean Data ANOVA 
Pyrexia Fisher’s Exact Test 
Reproductive Gilt/Piglet 
Viremia 
Animals positive Fisher’s Exact Test 
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Table 3. Nsp2 Mutations Causing Amino Acid Changes from Positive Piglets at Twenty-one 
Days of Age. 
 
Isolate MN184A Position Nucleotide 
Change 
Amino Acid Change 
MN184 #6 1468 A  G N D 
MN184 #6 2072 A  G N  S 
MN184 #6 2087 T  C L  P 
MN184 #6 2245 A G S G 
 JA142 AY424271 Position Nucleotide 
Change 
Amino Acid Change 
MR007 #2 3034 A  G N D 
MR007 #2 3097 G  A G  S 
MR007 #9 1738 G  A G  S 
MR007 #9 2684 C T S F 
MR007 #9 2941 T  G   G  W 
MR007 #9 3022 G  A G  S 
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Table 4. Mean Gilt Reproductive Performance per Litter. 
 
 
Total 
Farrowed 
Stillborn Healthy 
Live Piglets 
Weak 
Live 
Piglets 
Mummies DOF+21 
Live 
Pigs 
MN184 #6 9.00 1.75 6.25 0.25 0.50 6.50 
MR007 #2 8.25 2.50 5.75 0.00 0.00 5.25 
MR007 #9 11.25 0.25 9.50 1.00 0.50 9.75 
Negative 8.25 1.25 6.50 0.00 0.25 6.50 
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Figure 1. Pig Respiratory Trial: Lung Pathology. 
 
 
1 
The results were plotted as mean values of gross lung lesions from each group.  The letter a 
indicates the average lung score of the group is significantly higher than the negative control 
while the letter b indicates the group was significantly lower than the MR007 wt group (a/b = p < 
0.05). 
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Figure 2. Pig Respiratory Trial: Development of PRRSV Specific Antibody as Measured by 
IDEXX ELISA. 
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Figure 3: Gilt Reproductive Trial: Gilt Viremia as Detected by RT-PCR. 
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Figure 4. Gilt Reproductive Trial: Piglet Viremia as Detected by RT-PCR. 
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CHAPTER 5.  DISCUSSION 
General Conclusions 
Porcine reproductive and respiratory syndrome virus can be an elusive pathogen to 
routinely detect diagnostically and to control in commercial pork production.  The ability of the 
virus to constantly mutate has led to the development of a huge variety of isolates in the field.  
The breadth of isolates makes it difficult to detect all infections diagnostically and to provide 
commercial pigs with consistent cross protective immunity.  Stakeholders will continue to work 
with imperfect tools until significant advances are made in the basic understanding of 
determinants of immunity and viral pathogenicity. 
   The swine industry would undoubtedly benefit from the development of improved 
vaccines.  However, despite extensive efforts, little progress has been made to improve efficacy 
since the first introduction of a live, attenuated vaccine in 1994 [1].  The current lack of 
understanding of viral targets for protective immunity prevents guided attempts at developing 
vaccines with improved heterologous protection, increased safety, and the ability to differentiate 
vaccinated from wild type infected pigs.  Without a better understanding of PRRSV immunity 
and pathogenesis, the development of novel vaccines will likely rely on the current laborious and 
expensive trial and error approach. 
The two approaches reported here remain viable options to develop improved modified 
live vaccines, but have similar limitations.  Construction of protective chimeras will remain a 
guessing game until individual viral structures important for immunity are identified and can be 
targeted.  Likewise, without an understanding of the genomic basis of virulence it is impossible 
to determine the degree of virulence of isolates.  Potential vaccinates will require continued 
testing in live animals to determine attenuation and heterologous efficacy. 
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However, there is reason to remain optimistic for the outlook of improved disease 
prevention tools as scientists from around the world are actively seeking solutions.  Attempted 
strategies to develop improved vaccines have included: development of a vaccine after 
continuous passage of a highly virulent variant isolate (HP-PRRSV) in cell culture, genetic 
engineering of wild type strains, synthesis of infectious chimeras, creation of recombinant 
vectors expressing PRRSV proteins, development of DNA vaccines, and creation of plant made 
oral subunit vaccines [2].  Numerous strategies are being attempted by many bright investigators. 
Significant advances have already been made in the diagnostics realm allowing for 
improved detection of genetically divergent strains, earlier detection of infections, and continued 
development of differential assays.  In addition, the development of sample collection and 
delivery techniques allowing for the reduction of costs and technical training required for sample 
collection will be very beneficial to the pork industry.    
Development of improved vaccines against PRRSV will likely remain a challenge until 
the immunity and pathogenesis is better understood.  Additional research in PRRS 
immunobiology is urgently needed to hasten the development of better tools to help prevent, 
control, and eliminate the virus. 
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